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Prevention of cardiovascular diseases is known to postpone death, but in an aging 
society it is important to ensure that those who live longer are neither disabled 
nor suffering an inferior quality of life. It is essential both from the point of view 
of the aging individual as well as that of society that any individual should enjoy 
a good physical, mental and social quality of life during these additional years. 
Consequently, reports of the personal experience of how individuals consider the 
impact of disability or illness on their ability to function or their sense of well-being 
has become a vital addition to the overall assessment made of their health. 
The studies presented in this thesis investigated the impact of modi able risk 
factors, all of which affect cardiovascular health in the long term, on mortality and 
health-related quality of life (HRQoL). The hypothesis was that since much of the 
illness and disability in old age is related to cardiovascular risk factors in midlife, the 
existence of lower risk factors not only postpones death but also reduces disability 
and in rmity and thus provides a better quality of life in old age.
1.1 DATA AND METHODS
The data is based on the all male cohort of the Helsinki Businessmen Study. This 
cohort, originally of 3.490 men born between 1919 and 1934 has been followed 
since the 1960’s. The socioeconomic status of the participants is similar, since all 
the men were working in leading positions. Extensive baseline examinations were 
conducted among 2.375 of the men in 1974 when their mean age was 48 and at 
this time the health, medication and cardiovascular risk factors of the participants 
were observed. Among them a subcohort was established of 1.815 men who, in 
1974, were healthy and without chronic diseases or in need of medication. These 
three stages: the initial examinations in the 1960’s, examinations in 1974 and the 
identi cation of a healthy subcohort in 1974, constitute the basis for the substudies 
in this thesis. In 2000, at the mean age of 73, the HRQoL of the survivors of the 
original cohort was examined using the RAND-36 mailed questionnaire (n=1.864). 
RAND-36, along with the equivalent SF-36, is the world’s most widely used means 
of assessing generic health. The response rate was generally over 90% for the core 
questions. In 2002, a questionnaire among 633 men investigated their mental well-
being. Mortality was retrieved from national registers in 2000 and 2002. 
For the six substudies of this thesis, the impact of four different modi able 
cardiovascular risk factors (weight gain, cholesterol, alcohol and smoking) on 
the HRQoL in old age was studied both independently and in combination. The 
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follow-up time for these studies varies from 26 up to 39 years. Mortality is reported 
separately or included in the RAND-36 scores for HRQoL.  
1.2 RESULTS
Elevated levels of all the risk factors examined (weight gain, alcohol, cholesterol 
and smoking) among the participants in midlife led to a diminished life expectancy. 
This was the case when the risk factors were examined either individually or in 
combination.
Of the independent risk factors, weight gain in midlife increased mortality only 
in the highest weight gain group of over 15 kgs. Among survivors, lower weight 
gain was associated with better HRQoL. Men with no weight gain in midlife had 
consistently the best quality of life in old age, both physically and mentally.
Higher levels of serum cholesterol in middle age indicated both an earlier 
mortality and a decline in the physical component of HRQoL in a dose-response 
manner during the 39-year follow-up. The mental component of HRQoL did not 
differ between the lower and higher baseline cholesterol groups (serum cholesterol 
 5.0 or > 5.0 mmol/L).
The  ndings showed that mortality was signi cantly higher in the highest 
baseline category of reported mean alcohol consumption ( 5 drinks/day), but 
fairly comparable in abstainers and moderate drinkers during the 29-year follow-
up.  When HRQoL in old age was accounted for mortality by imputing deaths in 
the RAND-36 scores it emerged that men with the highest alcohol consumption in 
midlife clearly had poorer physical and mental health in old age, but the HRQoL of 
abstainers and those who drank alcohol in moderation were comparatively similar.
The amount of cigarette smoking in midlife was shown to have had a quantitative 
related effect on both mortality and HRQoL in old age during the 26 year follow-up. 
The men smoking over 20 cigarettes daily in middle age lost about 10 years of their 
life-expectancy. Meanwhile, the physical functioning of surviving heavy smokers in 
old age was similar to men 10 years older in the general population.  
The impact of clustered cardiovascular risk factors was examined by comparing 
two subcohorts of men who were healthy in 1974, but with different baseline risk 
factor status. The men with low risk had a 50 % lower mortality during the 29-years 
follow-up. Their RAND-36 scores for the physical quality of life in old age were 
signi cantly better. The mental scores of RAND-36 were not statistically different, 
but the 2002 questionnaire examining psychological well-being further indicated 
signi cantly better mental health among the low-risk group. 
7
1.3 CONCLUSIONS
The thesis of these studies is that favorable levels of cardiovascular risk factors 
earlier in life can postpone both death and the onset of disability and can also 
support well-being in old age. This hypothesis was examined in a homogenous 
cohort of men whose personal health and quality of life were assessed from middle 
age until survivors reached a mean age of 73. The results indicate that different 
risk factor levels in midlife have a meaningful impact on the quality of these extra 
years. Leading a healthy lifestyle improves both survival and the quality of life.
2 TIIVISTELMÄ (SUMMARY IN FINNISH)
Kehittyneiden maiden väestön odotettavissa oleva elinikä on lisääntynyt erityisesti 
sydän- ja verisuonisairauksien vähentymisen ansiosta. Yhä useammat saavat elää 
täyden elinkaaren, samalla kun yli 65-vuotiaiden osuus väestössä tulee lisääntymään 
vuosina 2010–2030.  Suomessa 80 % miehistä elää yli 65-vuotiaaksi, ja lähes puolet 
heistä saavuttaa 80 vuoden iän. 
Pitempään eläminen ei kuitenkaan automaattisesti takaa parempaa elämänlaatua, 
koska tällöin saattaa jäädä enemmän aikaa erilaisten pitkäaikaissairauksien 
aiheuttamalle toimintakyvyn alenemiselle. Keskeinen kysymys on, kannattaako 
elinikää pyrkiä pidentämään, jos se johtaa suureen määrään toimintakyvyttömiä 
vanhuksia, joiden oma elämänlaatu on huono, ja joiden hoito käy kansataloudelle 
kestämättömäksi. Tämän selvittämiseksi on arvioitava muitakin tekijöitä kuin 
kuolleisuutta ja sairastavuutta. 
Henkilön oma arvio hyvinvoinnistaan onkin tullut yhä tärkeämmäksi 
mittariksi perinteisten päätetapahtumien rinnalle sekä yksilön, että yhteiskunnan 
näkökulmasta. Elämänlaadun luotettava mittaaminen on kuitenkin tullut 
mahdolliseksi vasta validoitujen kysymyssarjojen kuten RAND-36, tultua 
laajempaan käyttöön.
Viimeisten elinvuosien elämänlaatuun vaikuttavia tekijöitä arvioitaessa on 
myös kuolleisuus otettava huomioon: poikkileikkaustutkimuksessa saadaan tietoa 
vain eloonjääneiltä, usein siis jo pitkälle valikoituneesta, terveemmästä joukosta. 
Seurantatutkimuksen tuloksissa tämä voidaan ottaa paremmin huomioon. Toisaalta 
verisuonisairauksien riskitekijät, kuten esimerkiksi tupakointi, alkavat vaikuttaa 
jo nuorella iällä, saattaen siten vaikuttaa eri ryhmien terveyseroihin jo keski-iässä, 
ennen seurantatutkimuksen alkua.
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2.1 HELSINGIN JOHTAJATUTKIMUS 
 (HELSINKI BUSINESSMEN STUDY)
Tämän väitöskirjan osatutkimusten tavoitteena oli selvittää, miten elintavat ja keski-
iässä esiintyvät tavallisimmat sydän- ja verisuonisairauksien riskitekijät vaikuttavat 
elämänlaatuun vanhalla iällä.
Tulokset perustuvat ns. Helsingin Johtajatutkimuksen aineistoon.  Helsingin 
Johtajatutkimuksessa on seurattu 1919–1934 syntyneiden 3 490 suomalaisen 
miehen terveydentilaa 1960-luvulta nykypäiviin saakka. He kuuluivat ylimpään 
sosiaaliryhmään. 
Vuonna 1974, jolloin kohortin keski-ikä oli 48 vuotta, miehille suoritettiin 
laajat elintapoihin ja terveyteen liittyvät selvitykset, joiden perusteella voitiin valita 
seurantaan ne henkilöt, jotka olivat terveitä ja joilla ei ollut säännöllisiä lääkityksiä, 
mutta joiden riskitekijätasot vaihtelivat matalasta korkeaan. 
Vuonna 2000, jolloin elossa olevien keski-ikä oli 73 vuotta, tutkittaville lähetettiin 
kirjekysely, jolla selvitettiin elintapoja (mm liikunta, tupakointi ja alkoholinkäyttö), 
sekä sairauksia ja niiden riskitekijöitä.  Kyselyyn sisältyi myös terveyteen liittyvän 
elämänlaadun mittari RAND-36 (RAND 36-Item Health Survey 1.0, yhteneväinen 
SF-36® -mittarin kanssa), jonka suomenkielinen versio on validoitu suomalaiselle 
väestölle. 
2002–2003 tutkittaville lähetettiin lisäksi henkistä hyvinvointia tarkemmin 
kartoittava kirjekysely. Tutkimuskohortin kuolleisuutta on seurattu Väestörekisteristä 
31.12.2002 saakka.
Tutkimuksen vahvuuksina ovat pitkä seuranta-aika, sosioekonomisesti 
homogeeninen tutkimusjoukko, sekä laajat lähtövaiheen perustiedot, jotka 
mahdollistavat sekoittavien tekijöiden huomioimisen tuloksissa. Kohortin 
valikoituneisuuden vuoksi esitettyjen tulosten soveltamiseen eri-ikäisiin tai eri 
sosiaaliluokkaan kuuluviin miehiin, ja erityisesti naisiin on kuitenkin suhtauduttava 
varauksellisesti. 
2.2 OSATUTKIMUS I: VARHAISESSA KESKI-IÄSSÄ 
 TAPAHTUNEEN PAINONNOUSUN YHTEYS KUOLLEI-
 SUUTEEN JA MYÖHEMMÄN IÄN ELÄMÄNLAATUUN.
Väitöskirjan I osatutkimuksessa selvitettiin varhaisessa keski-iässä tapahtuneen 
painonmuutoksen yhteyttä myöhemmän iän elämänlaatuun. Kohortti jaettiin 
viiteen eri ryhmään 25 ikävuodesta vuoteen 1974 (keski-ikä 46 vuotta) tapahtuneen 
painonnousun mukaan. Tulosten mukaan vain suurin painonnousu, yli 15 kg, ennusti 
lisääntynyttä kuolleisuutta seuranta-aikana. Sen sijaan vanhuusiän elämänlaatu 
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oli suorassa yhteydessä aiemman painonmuutoksen suuruuteen 26 vuoden 
seurannassa: miehillä, joiden paino ei noussut keski-iässä, oli paras elämänlaatu 
vanhuksena, ja mitä enemmän paino oli noussut, sitä huonompi sekä fyysinen että 
psyykkinen elämänlaatu oli seurannassa kaikilla RAND-36 mittarin kahdeksalla osa-
asteikolla. Erityisen selvästi elämänlaadun erot tulivat esiin fyysisen toimintakyvyn 
ja fyysisen roolitoiminnan asteikoilla, heijastaen toiminnanvajavuuden (disability) 
kehittymistä.
2.3 OSATUTKIMUS II: KESKI-IÄN KOLESTEROLITASON YHTEYS 
KUOLLEISUUTEEN JA MYÖHEMMÄN IÄN ELÄMÄNLAATUUN.
Osatutkimuksessa II tutkittiin keski-iän (keskimäärin 38 vuoden iässä) 
kolesterolitason yhteyttä kuolleisuuteen ja vanhuusiän elämänlaatuun. 39 vuoden 
seuranta oli aloitettu ennen nykyaikaisten kolesterolia alentavien lääkkeiden 
käyttöön tuloa.  Perusvaiheen kolesterolitasolla oli suora yhteys kuolleisuuteen 
seuranta-aikana: Kuolleisuus lisääntyi noin 11 % jokaista 1 mmol/L kolesterolitason 
nousua kohden. Myös elämänlaatu huononi korkeamman kolesterolitason myötä: 
Keski-iässä alimman kolesterolitason (alle 5,0 mmol/L) omaavien miesten 
fyysinen elämänlaatu oli vanhemmalla iällä parhain kaikilla RAND-36 mittarin 
asteikoilla verrattuna tätä korkeamman kolesterolitason omaaviin miehiin. Fyysisen 
terveydentilan kokoomamuuttuja oli erittäin merkitsevästi parempi pienimmän 
kolesterolitason ryhmässä. Tämä piste-ero vastaa toiminnanvajavuuden siirtymistä 
noin kolmella vuodella eteenpäin niiden hyväksi, joiden kolesterolitaso keski-
iässä oli matala. Psyykkisen terveydentilan kokoomamuuttujan pisteet sen sijaan 
olivat lähes identtiset. Lähtövaiheen matalaan kolesterolitasoon ei siis liittynyt 
psyykkisen elämänlaadun heikentymistä vanhalla iällä – mutta ei myöskään selkeää 
paranemista.
2.4 OSATUTKIMUS III: KESKI-IÄSSÄ TAPAHTUNEEN 
 ALKOHOLINKÄYTÖN YHTEYS KUOLLEISUUTEEN 
 JA VANHEMMAN IÄN ELÄMÄNLAATUUN.
Osatutkimus III selvitti keski-iässä tapahtuvan alkoholin käytön yhteyttä 
kuolleisuuteen ja myöhemmän iän elämänlaatuun. Helsingin Johtajatutkimuksen 
ryhmän sosiaalinen homogeenisyys vähentää sosioekonomisten erojen aiheuttamaa 
virhevaikutusta. Myös poikkeuksellisen pitkä seuranta-aika, 29 vuotta, lisää 
tulosten luotettavuutta, joskin muutokset tutkittavien alkoholin käytössä voivat 
olla sekoittava tekijä pitkässä seurannassa. Tutkimukseen osallistuneet miehet 
jaettiin keski-iässä raportoidun alkoholin käyttömäärän perusteella kolmeen 
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ryhmään: nolla-käyttäjät, kohtuukäyttäjät (1-3 annosta/päivä) ja suurkuluttajat 
(yli 3 annosta/päivä). 29-vuoden seurannassa kuolleisuus oli samaa suuruusluokkaa 
sekä nollakäyttäjillä (25 %) kuin kohtuukäyttäjilläkin (27 %), sen sijaan selvästi 
korkeampi (38 %) suurkuluttajien kohdalla. Sydän- ja verisuonisairauksista 
johtuvassa kuolleisuudessa ei sen sijaan ollut eroa eri ryhmien välillä.  Ryhmien 
välillä ei ollut selkeitä eroja elämänlaadussa vanhalla iällä, ei fyysisen eikä psyykkisen 
komponentin osalta. Sen sijaan, kun myös kuolleet huomioitiin elämänlaatua 
laskettaessa (heikkona elämänlaatuna), oli elämänlaatu suurkuluttajien ryhmässä 
selvästi huonompi kuin alkoholia vähemmän kuluttavien ryhmissä.  Toisaalta 
nollakäyttäjienkään kuolleisuus ei ollut kohtuukäyttäjiä suurempi viitaten siihen, 
että pitkällä aikavälillä alkoholin kohtuukäytöstä ei välttämättä ole terveydellistä 
hyötyä abstinenssiin verrattuna. 
Kun laskennassa otettiin huomioon se, että suurimpaan alkoholinkulutta-
jaryhmään liittyi myös runsaammin muita riskitekijöitä (mm. tupakointi, vähäinen 
liikunta, korkeampi verenpaine) ja näiden tekijöiden vaikutus eliminoitiin 
kuolleisuutta laskettaessa, ei alkoholin käyttö enää yksinään sinänsä lisännyt 
kuolleisuutta. Alkoholia enemmän kuluttaneiden suurempi kuolleisuus näyttää 
siis liittyvän enemmänkin alkoholin käyttöön liittyviin muihin riskitekijöihin 
kuin alkoholin itsenäiseen vaikutukseen tässä mieskohortissa, joka oli keski-iässä 
terve ja työkykyinen. On lisäksi huomioitava, että alkoholin ongelmakäyttö oli 
poissulkukriteeri tässä tutkimuksessa.
2.5 OSATUTKIMUS IV: KESKI-IÄSSÄ TAPAHTUNEEN    
 TUPAKOINNIN YHTEYS KUOLLEISUUTEEN JA    
 VANHEMMAN IÄN ELÄMÄNLAATUUN.
Neljännen osatutkimuksen tulokset keski-iässä tapahtuneen tupakoinnin 
yhteydestä kuolleisuuteen ja vanhemman iän elämänlaatuun osoittivat, että keski-
iässä tupakoimattomat miehet elivät 10 vuotta pitempään kuin yli 20 savuketta 
päivässä polttaneet.  Tämä siitä huolimatta, että lähes 70 % tupakoitsijoista oli 
lopettanut tupakoinnin seuranta-ajan kuluessa. Tupakoimattomien miesten 
elämänlaatu oli 26 vuoden seurannassa paras kaikilla RAND-36 mittarin asteikoilla 
mitattuna. Erityisen suuret erot keski-iässä tupakoineisiin nähden nähtiin fyysisessä 
toimintakyvyssä ja fyysisten ongelmien aiheuttamissa roolitoiminnan rajoitteissa. 
Eloonjääneiden tupakoitsijoiden fyysinen toimintakyky oli tasolla, joka keskimäärin 
vastasi 10 vuotta vanhemman suomalaisen miesväestön toimintakykyä RAND-36 
mittarin Fyysinen toimintakyky -asteikolla mitattuna.
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2.6 OSATUTKIMUS V JA VI: VERISUONISAIRAUKSIEN 
 RISKITEKIJÖIDEN KASAUTUMINEN KESKI-IÄSSÄ,   
 KUOLLEISUUS JA ELÄMÄNLAATU VANHALLA IÄLLÄ.
Osatutkimuksessa V ja VI verrattiin keski-iässä korkean ja matalan 
valtimosairauksien riskitekijätason omaavien, mutta muuten terveiden 
miesten kuolleisuutta ja elämänlaatua 26 vuoden seurannan aikana. Sydän- ja 
verisuonisairauksien riskitekijöiden kasautuminen aiheutti yli 50 % suuremman 
suhteellisen kuolleisuuden seuranta-aikana. Eloonjääneistä miehistä niillä, joiden 
valtimosuonisairauksien riskitekijätaso keski-iässä oli matalampi, oli seurannassa 
kauttaaltaan myös parempi elämänlaatu kuin niillä, joilla oli yksi tai useampia 
riskitekijöitä: RAND-36 mittarin kaikki kahdeksan asteikkoa osoittivat parempaa 
elämänlaatua. Kokoomamuuttujista myös fyysistä terveydentilaa kuvaava PCS 
oli parempi, mutta psyykkistä terveydentilaa kuvaava kokoomamuuttuja MCS ei 
merkitsevästi eronnut ryhmien välillä. 
Kuitenkin, kun osatutkimuksessa VI selvitettiin näiden ryhmien henkistä 
hyvinvointia erillisellä kartoituksella vielä laajemmin, kuin mitä RAND-36 
kysymyssarja mahdollistaa, todettiin eroja myös psyykkisen elämänlaadun 
osalta. Kyselykaavakkeilla selvitettiin masennusoireita, onnellisuuden tunnetta 
ja positiivista elämänasennetta. Tulokset olivat järjestelmällisesti parempia 
matalan riskiryhmän hyväksi. Merkitsevät erot nähtiin elämään tyytyväisyydessä, 
onnellisuudessa, positiivisessa elämänasenteessa, Zungin depressiopisteissä sekä 
yleisessä terveydentilassa.  
Tulokset kuvastavat sitä, että keski-ikäisenä matalan riskitason omaavat miehet 
vanhenivat myös psyykkisesti terveempinä kuin korkean riskin miehet.
2.7 YHTEENVETO
Elintapoihin, kuten ruokailutottumuksiin, tupakointiin tai alkoholinkäyttöön 
liittyvät valinnat vaikuttavat oleellisesti elämämme pituuteen. Pitempi elämä 
ei kuitenkaan takaa parempaa terveyttä tai parempaa elämänlaatua, etenkään 
elinkaaren lopussa. Pitkäikäisille jää enemmän aikaa sairastua valtimotauteihin tai 
muihin kroonisiin sairauksiin, jotka saattavat alentaa toimintakykyä ja elämänlaatua. 
Väestön ikääntyessä ihmisten viimeisten vuosien itsenäinen toimintakyky, sekä 
henkinen ja sosiaalinen hyvinvointi ovat keskeisiä sekä yksilön että yhteiskunnan 
kannalta. Tämän vuoksi elämänlaadun arvioinnista on tullut tärkeä mittauskohde 
kuolleisuuden ja sairastavuuden rinnalle. 
Tässä väitöskirjassa esitettyjen tutkimustulosten mukaan valtimosairauksien 
matala riskitekijätaso keski-iässä ja myöhemminkin lisää merkittävästi vanhuusiän 
elämänlaatua, erityisesti fyysistä toimintakykyä, mutta usein myös psyykkistä 
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hyvinvointia. Terveelliset elintavat siis paitsi lisäävät elinvuosia, myös parantavat 
niiden laatua. Täyden hyödyn saamiseksi riskitekijöiden tunnistamisen ja hoidon 
tulisi tapahtua riittävän varhaisessa vaiheessa, keski-iässä tai nuoruudessa. Tieto 
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6 INTRODUCTION
Life can only be understood backwards; but it must be lived forwards. 
(Søren Kierkegaard, Danish philosopher (1813 - 1855))
The world’s population is aging.1 Globally this is due to reduced fertility and increased 
life expectancy.  In the developed societies this is mainly because of the great birth 
rate after the two decades following WW2, while advances in public health through 
behavioral changes, nutrition and improved medical care have diminished mortality. 
Consequently, there will be more people who can expect to live a full lifespan 
and an increased number of persons over 65 years of age during the years 2010-
2030.2  In Finland 80% of men and 90 % of women are expected to live to the age 
of 65 years or older. The age of 80 is reached by nearly one-half of men and 70 per 
cent of women.3 The increase in life-expectancy is largely attributed to a decline in 
cardiovascular mortality via a reduction in major risk factors as well as advances 
in the treatment of these diseases. 
 As people reach older ages, also the morbidity of chronic diseases and subsequent 
disability and functional impairment among the population is anticipated to increase. 
This has highlighted the importance of improving the quality of life and functional 
abilities of older adults, both from the individual as well as the societal point of 
view. Subsequently, an individual’s own view on his or her well-being has become 
an increasingly signi cant measure of health along the traditional measures such as 
mortality and morbidity. The development of validated questionnaires, for example 
RAND-36, has made it possible to collect information on this subjective health 




7 REVIEW OF THE LITERATURE
7.1 HEALTH-RELATED QUALITY OF LIFE
7.1.1 DEFINITION OF QUALITY OF LIFE
Quality of life (QoL) remains still poorly de ned today.  It is a multidimensional 
concept that refers to the overall well-being of individuals.4 In the broadest sense it 
includes major economical, social and environmental components besides health, 
such as literacy, income and freedom. This general view is represented in the United 
Nations Development Program’s Human Development Index, HDI5, which is the 
best known composite quality of life scale. 6  This index was developed in order to 
make comparisons between different countries. It gives a single value measuring 
health and longevity, knowledge (literacy and school enrolment) and standards of 
living (GDP per capita).  Numerous other indices have been developed to measure 
quality of life. As basic markers they typically include factors such as income, 
employment, poverty, health status, family issues and pollution levels.6
However, many of the non-economic aspects of the quality of life are subjective 
and cannot be objectively measured.  Thus seve ral indices, for instance the WHOQOL 
7 8 questionnaires have been constructed to encompass not only the quality of life 
circumstances, but also dimensions that cover an individual’s perceptions and 
feelings to his living conditions in the context of his environment, culture, values, 
and experiences, including measures of satisfaction or happiness.9 10  Spilker et 
al. have divided the concept of quality in life in gerontological research into two 
distinct concepts: the health-related quality of life (HRQoL) and the non-health 
environmental-based quality of life. 11 
7.1.2  DEFINITION OF HEALTH-RELATED Q UALITY OF LIFE
The World Health Organization (WHO) has in 1948 de ned health as being not only 
the absence of disease but also the presence of physical, mental, and social well-
being: ‘‘A state of complete physical, mental and social well-being and not merely 
the absence of disease or in rmity.’’ 12  This de  nition of health thus considers also 
aspects related to the quality of life (QoL).  Subsequently, the concept was expanded 
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to also include health-related quality of life (HRQoL), when in 1993 WHO presented 
a de nition of quality of life linked to health: “An individual’s perception of his/
her position in life, in the context of the culture and value systems in which he/
she lives and in relation to his/her goals, expectations, standards and concerns”. 7
It meant a decisive shift from measuring only ill health and its manifestations 
with tr aditional measures such as morbidity and mortality, to measuring health 
status multidimensionally with additional measures such as physical functioning, 
cognitive and emotional functions and self-perceived health.
There is a variety of other de nitions also for the HRQoL, but they all have in 
common that the emphasis is upon the perspective of the individual. For example, 
the Encyclopaedia of Aging de nes that “HRQoL refers to how health impacts on 
an individual’s ability to function and his perceived well-being in physical, mental 
and social domains of life”.13
7.1.3  MEASURING HEALTH-RELATED QUALITY OF LIFE
HRQoL may be measured for various purposes, principally in order to 1) differentiate 
the health status between groups, 2) evaluate change over a period of time or 3) 
predict future health states.14  Subsequently different prerequisites are needed for 
the pro le of the HRQoL instrument in question, according to the rationale. Ideally a 
HRQoL instrument should be able to perform two important properties: To measure 
important health domains widely, and to have the ability to integrate the data 
from the individual d omains into an overall score.15 An overall score is required 
for cost-utility evaluations.  Typically HRQoL domains include an assessment of 
functiona l status (e.g. how long a person is able to walk or run, whether he is able 
to do housework or bathe or dress independently), emotional well-being or mental 
health (e.g. signs of depression or anxiety or positive affect), social involvement (e.g. 
engagement in activities) and symptom states (e.g. pain, sleep).  A common feature 
of HRQoL domains is that they include characteristics of life which are affected by 
changes in health. Jaschke et al. have de ned that HRQoL domains are aspects of 
life that improve when a physician successfully treats a patient.16
7.1.3.1  Types of measure
According to Fitzpatrick 17 and Garratt et al. 18 HRQoL questionnaires are divided 
into different types of measure:                              
1) Dimension speci c measures usually produce a single score focusing on a speci c 
aspect of health, for instance the Zung Self-Rating Depression Scale.19
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2)  Disease or population targeted measures are aimed to be used in speci ed 
diseases such as asthma or arthritis, for instance the Asthma Quality of Life 
questionnaire.
3) Generic measures are designed to be responded to by anyone so that they 
are applicable across all diseases and conditions, across different medical 
interventions and across a wide range of populations and they usually include 
a number of health domains. Generic measures have the advantage to compare 
the health state of different groups, for instance the young and the old or the ill 
and the healthy, and to make comparisons of the burden of disease in different 
conditions and to compare the bene ts of different treatments. For instance The 
RAND 36-Item Health Survey. 20 
4) Indivi dualized measures permit respondents to assess and value aspects of their 
own life; usually to generate a single score, for instance the patient generated 
index.21 
5) Utility measures have been developed for purposes of economic evaluation. They 
focus on preferences for health states. They produce a single index for use in 
economic evaluation. For instance EuroQoL 22 and Health Utilities Index 23.
Another categorization of HRQoL measures divides them into disease-speci c 
and generic measures, as suggested by Patrick 24 and Fayers 25. 
1) Disease-targeted HRQoL measures are aimed to be used in speci ed diseases 
such as depression or arthritis.
2) Generic measures, as described above, can be used to assess the health of both 
general and speci c populations. Generic measures are further divided into two 
types of generic HRQoL measures: 
a) Pro le measures, such as RAND-36, which give scores on multiple aspects 
of HRQoL. 
b) Contrary to this, preference-based generic HRQoL measures produce a single 
summary score for HRQoL, which is needed especially when an economic 
value of the change or differences of treatment is to be evaluated. 
7.1.3.2  Reliability and validity
The HRQoL instrument used in research or a clinical study has to be reliable 
and valid. Psychometric methods are used to establish the quality of the HRQoL 
instrument and the measurements.  
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7.1.3.2.1 Reliability
In the context of a HRQoL instrument with multi-item scales, reliability is usually 
measured by examining its internal consistency and test-retest reliability. Higher 
reliability indicates that random error has less part in the results.  
The internal consistency reliability of a HRQoL survey instrument re ects how 
well different questionnaire items are interrelated and thus indicates whether 
their combination in an index is justi ed. The most common method to test 
this is Cronbach’s alpha (). 26  It ranges from zero to one; commonly for group 
comparisons an  of 0.7-0.8 is regarded to indicate acceptable reliability and 0.8 or 
higher indicates good reliability. 27 In a multi-item questionnaire Cronbach’s alpha 
depends on the number and the homogeneity of the items.  Reliability can thus be 
increased by increasing the number of items in the questionnaire. 28  However, this 
may have a negative effect on the feasibility of the questionnaire.  
The test-retest method is needed to evaluate reliability, if the questionnaire is 
administered several times. A reliable HRQoL instrument should be able to give 
the same score for the same person or group each time it is administered, when 
there has been no change in the attribute that is measured.  
7.1.3.2.1 Validity
It is important that a HRQoL scale is valid for the speci c application in the 
determined population. Validity refers to whether the HRQoL instrument measures 
what it is expected to measure. 
In general there are three kinds of validity used for the evaluation of a HRQoL 
survey instrument:  Content validity, construct validity and criterion-related validity. 29 
Content validity means the ability of the HRQoL instrument to cover all the 
aspects of health dimensions that were intended to be evaluated. 
Construct validity re ects to the ability of a test to measure the concept that it 
is supposed to measure. It is often evaluated by examining the relationship of the 
item to be validated to other related items in the survey. 
Criterion-related validity is examined by comparing the results of the test 
instrument to the results given by another instrument regarded as the golden 
standard for this purpose. 
Floor and ceiling effects are concepts that may affect the criterion validity of a 
HRQoL instrument. Floor effect takes place when the HRQoL instrument cannot 
differentiate those respondents whose scores are at the bottom of the scale. Ceiling 
effect is the opposite phenomenon at the top of the scale. For instance, asking a 
group of joggers whether they can walk 2 kilometers does not distinguish possible 
differences in their  tness, producing a ceiling effect. Respectively, if the question 
is posed to people in wheelchairs, a  oor effect is apparent. 
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The instrument measuring HRQoL should also detect change in a clinical 
intervention. In a cross-sectional study an ability to distinguish among groups in 
a point in time is required. The capability to detect within-person change over time 
and ability to predict subsequent health status are needed in a longitudinal study.30 
In addition, the concept of responsiveness, de ned as the capability of an 
instrument to detect clinically relevant change over time, has been added to the 
basic quali cations of an evaluative HRQoL tool. 31  However, its de nition varies 32 
and furthermore, it has been repeatedly debated whether this is a distinct asset of 
HRQoL questionnaires separate from reliability and validity, or simply a measure 
of longitudinal validity or of treatment effect. 33 
7.1.3.3 Person reported information
A central feature of practically all HRQoL measures is that individuals themselves 
rate their level of disability or well-being. Questionnaires assessing the HRQoL of 
the respondents are an easy and inexpensive way to collect information about the 
health of the participants and the course and changes of their health over time.  As 
a result, self-administered questionnaires have nowadays been widely accepted for 
use in clinical studies of large population samples as they enable gathering data 
from a large cohort simultaneously at a lot less expense than clinical assessments. 
Furthermore, the relative privacy of the respondent may diminish bias resulting from 
incomplete or false answers to questions that the participant  nds inappropriate 
or too personal in interviews.
Single global assessments with a one-item questionnaire of self-perceived health 
or HRQoL have been used when a single score for a patient is needed for instance 
for health economics or policy making. However, most HRQoL instruments are 
multi-item questionnaires, covering the many aspects of HRQoL.
7.1.3.4 RAND-36
The RAND 36-Item Health Survey (Version 1.0)  / The MOS 36-Item Short Form 
Health Survey (SF-36®) was developed in 1988-1990 from the data gathered from 
a cohort of over 20.000 patients participating in the Medical Outcomes Study 
(MOS). 20 34 MOS was a mu lti-year, non-experimental study of patient outcomes 
conducted  in the U.S. during the 1980’s. 35 The HRQoL measures in the MOS study 
were gathered by self-administered questionnaires consisting of 116 items covering 
the two dimensions of health: physical and mental health. With further analysis 
and development, these questions were later cut down to a subset of 36 items 
re ecting functioning and well-being. This 36-item set is currently distributed by 
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different organizations, with subsequently different names. The RAND organization 
is distributing the set as the RAND 36-Item Health Survey 1.0 (RAND-36), the 
Medical Outcomes Trust as the MOS 36-Item Short Form Health Survey (SF-36) 
36 , the Health Outcomes Institute as the Health Status Questionnaire and the 
Psychological Corporation as the RAND-36 Health Status Inventory. 
 By 1991, RAND-36 had been shown to be a reliable, valid and responsive 
instrument in measuring HRQoL by several clinical studies in the U.S.  18  37  Research 
ha d shown it to be a comprehensive measure of generic health status that was 
applicable across heterogeneous populations, including older people. 38 39  Due 
to its shortness it could be supplemented with other generic and disease-speci c 
measures in clinical studies.  During the 1990’s, studies in several European countries 
showed that it could be translated successfully. The Finnish version of RAND-36 
was jointly developed by RAND, Stakes and Kansanterveyslaitos in 1994. 40 It has 
been  validated as a mailed questionnaire also for the Finnish general population 
with age- and sex-matched population norms.
According to a systematic search of electronic databases in 2002, RAND-36/
SF-36 is the most widely used generic health outcomes instrument in the world. 
41 It accounted for over 10% of the total number of reports, including those using 
disease-speci c measures, and more than 60% of those using a generic measure. 
Translations are available for more than 60 countries and more than 5.000 papers 
have been published using RAND-36/SF-36 to measure HRQoL.  42 Despite simi lar 
wording in the questions, the scoring algorithm for the scales of bodily pain and 
general health somewhat differ between RAND-36 and SF-36.  However, these 
differences have been shown to be of minor importance and do not have a meaningful 
effect on the scale scores. 34 A practical difference in using these questionnaires is 
that the MOS Trust Corporation demands permission for use and strict adherence 
to item wording and scoring recommendations in order to allow the use of the SF-
36 trademark, whereas the RAND-36 questionnaire is freely distributed without 
copyright protection.
7.1.3.4.1 Construction of RAND-36
The RAND-36 /SF-36 questionnaire is comprised of 36 items (questions) that assess 
eight domains of HRQoL: 
1) Physical functioning:
Includes ten items, describing to what extent the respondent’s health limits his 
or her physical activities such as walking distance, ability to climb stairs, lifting 
objects, bending or kneeling.
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2) Role limitations caused by physical health problems: 
Includes four items describing limitations in activities caused by physical 
problems,   
3) Role limitations caused by emotional problems: 
Three items, describing limitations in activities that are due to emotional 
problems,    
4) Social functioning:  
Two items covering the extent of limitations in normal social activities caused 
both by physical or mental factors,
5) Emotional well-being: 
Five items covering happiness, anxiety and depression,
6) Energy/fatigue: 
Four items re ecting the respondent’s vitality and tiredness, 
7) Pain: 
Two items on the magnitude of pain and the amount it interferes with daily 
activities,
8) General health perception: 
Five items on self-perceived conception on one’s current health, current health 
state compared to others, future health and resistance to illness. 
The 36 th item (question number 2) in the RAND-36 questionnaire is a single 
item that assesses the change in perceived health during the past 12 months.  It is 
not counted into the scales or summary scores. 
Responses to these 36 questions vary from dichotomous (two answers e.g. yes 
or no) up to six alternatives in answers (e.g. none/some of the time/most of the 
time etc.), with  ve or six options being the most common response categories.
All items are transformed linearly such that the lowest and highest scores are 
set at 0 and 100, respectively. Thus all scales scores range from 0 to 100, with 100 
representing the most favorable functioning or well-being, and the scale scores 
characterize the percentage of total possible score that can be attained. 
7.1.3.4.2  RAND-36 component summary scores
The eight domains of RAND-36 are further aggregated into two summary measures: 
the physical (PCS) and mental (MCS) health component summary scores. These 
summary scales are standardized so that the mean (+/- SD) for the validated 
population is 50 (+/- 10). Subsequently, for example a score under 50 is thus 
below the general population mean, and each point corresponds to 1/10th of a 
standard deviation. The summary measures have not been validated in the Finnish 
population.   
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7.1.3.4.3  Reliability and validity of RAND-36
Since RAND-36 can be utilized in various different populations, in different 
languages and for diverse applications, evidence of its reliability and validity is 
essential for its use.
The validity of the RAND-36 scales has been analyzed as part of the MOS study 
core measures by means of content, construct, and criterion validity. 20 Also data 
from clinical studies and population surveys have been assessed for this purpose. 
37 The scales have also been evaluated for reliability coef cients such as inter-rater 
reliability, internal consistency reliability and test-retest reliability. Estimated with 
Cronbach’s alpha coef cient the RAND-36 scales were shown to be reliable both 
for group and individual cmparisons. 43  
While the multi-item structure of generic measures such as RAND-36 conveys 
many bene ts, small changes in responses may be hidden behind the stability of 
the other items and thus reduce the responsiveness of the instrument. 44 
7.1.3.4.4  Minimal clinically important difference 
A small difference in a HRQoL score may in a clinical study be statistically, yet 
not necessarily clinically signi cant. The concept of minimal clinically important 
difference (MCID) has been created to denote the smallest difference in an outcome 
measure e.g. a HRQoL score that would still be clinically important. For instance, 
in a clinical study, a change in a HRQoL domain that gives reason for a change in 
treatment can be regarded as a clinically signi cant change. 16 
Although MCID standards have not been clearly established for the RAND-36, 
a difference of 3 to 5 points has been suggested. 45 46 Changes i n scores that exceed 
one standard error of measurement (SEM) have also been regarded as a signi cant 
clinical change for RAND-36. 47  (SEM is calculated as SD (1 – R) where SD is the 
SD of the baseline domain score and R is the domain reliability.) In a meta-analysis 
of 38 studies using different HRQoL instruments, Norman et al. found that MCID 
was consistently very close to one half a SD in these studies. 48
7.1.3.4.5  The predictive value of RAND-36
Self-assessed health status has been shown to be a strong predictor of subsequent 
mortality and morbidity 49 50, and this has also been demonstrated for the RAND-36/ 
SF-36 questionnaire 45, also among older persons 51. 
The RAND-36/SF-36 questionnaire was developed from the data gathered in 
the Medical Outcomes study. In this study the 5-year mortality rates of chronically 
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ill participants increased markedly with the decline in PCS scores. 45  The mortality 
was 21.5% for those whose PCS score was 8- 24; 15.1% for PCS score 25-34; 6.2% 
for PCS score 35-44; 4.7% for PCS score 45-54, and 1.8% for PCS score 55-72. 
Kroenke et al. examined the predictive value of the SF-36 instrument for mortality 
among healthy middle aged women in a large sample of the Nurses’ Health study 
population, showing that women with low PCS and MCS scores had the highest 
mortality during the 4-year follow-up. 52  A great decline in PCS was associated with 
over a three-fold relative risk compared to those women with no change in PCS. 
Improvement in PCS was associated with lower mortality. Results for the MCS 
score were similar. In a study of 2.166 older participants with chronic diseases, 
the PCS of SF-12, the shortened version of SF-36, predicted higher mortality and 
hospitalization during two years of follow-up.53 In another prospective study of 7.702 
participants a decline of more than 10 points in the PCS score was associated with 
over two-fold increased risk for mortality and 1.8 fold risk for hospitalization during 
a year of follow-up. 54 An increased risk was also seen with a more than 10-point 
decrease i the MCS: 1.6 fold risk for morality and 1.5 fold risk for hospitalization. 
Also in the healthy and relatively young cohort of the Whitehall II study, SF-36 was 
shown to be able to detect changes in the health status in the general population. 55 
Additionally, the Physical functioning scale has been shown to be independently 
comparable to other instruments measuring disability in older people. 56 While in 
some s tudies the patients’ own assessments of their physical functioning seems 
to differ from the evaluation made by a physician,57 a systematic review of trials 
showed that on average the doctors’ global assessments of treatment effects are 
comparable to those of patients. 58 
 7.1.3.4.6  Floor and ceiling effect  
Using SF-36 in the general population,  oor effects have been observed in the two 
Role limitations scales in the general U.S. population.59 The ceiling effect has been 
observed for the two Role limitations scales as well as for Social functioning. In a 
study of healthy older participants, some tendency for ceiling measurement effects 
was seen in two physical scales of SF-36. 60 Whether these effects are imposed in 
very ill patients has not been determined.61 In the Finnish general population  oor 
effects were found in the Role limitation scales and stronger ceiling effects were 
apparent in the scales of Role limitations, Physical functioning, Social functioning 
and Bodily pain of the RAND-36 instrument. These effects were stronger than those 
found in the U.S. general population.40
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7.1.3.4.7   Missing data
A possible limitation of self-administered questionnaires especially in studies 
involving older persons is missing data.62 Although they are easier and cheaper to 
perform than personal interviews, the amount of missing data is greater in mailed 
questionnaires. Missing responses may lead to bias by diminishing the power of 
analysis or enhancing variation in parameter estimates. The amount of missing 
data may increase according to the age of respondents. In the MOS study older 
patients were more likely to miss an item within a given HRQoL measure; 12 % of 
respondents 75 years or older had missing data for at least one of the 10 items of 
the PF scale.63 However, very few patients in any age-group missed all items in a 
measure. Higher education diminished the rate of missing data. In this study, 10% 
of participants over 75 years and with poor physical or mental health felt unable to 
self-complete the SF-36 questionnaire and  26% of them left out at least one of the 
36 items. Also missing statements were signi cantly related to older age. Parker et 
al. found that overall functional impairment, cognitive impairment and impaired 
manual dexterity were associated with the number of uncompleted items, whereas 
cognitive impairment, age and visuospatial problems increased the time to complete 
the SF-36 questionnaire.64 
On the other hand, in a multi-item questionnaire, such as RAND-36/SF-36, 
the missing data may be imputed by an estimation of the respondent’s answers to 
the other items in the scale. This increases the reliability of the RAND-36 HRQoL 
instrument compared to a measure using only one or two items. 
In end-of-life studies, such as the Helsinki Businessmen Study, also death leads 
to missing data. When two groups are compared, the group with higher mortality 
and missing data will be likely to have the most favorable data, if deaths are not 
accounted for. Diehr et al. have developed a coding for self-perceived health that 
encompasses death as an outcome, offering an approach to combine self-assessed 
scores with mortality data. 65 66 These analyzes produce new alternate values for 
PCS and MCS where the dead areo coded as zero.
7.2 SUCCESSFUL AGING
7.2.1 DEFINITION
In 1998 WHO introduced the concept of active aging: “Active aging is the process of 
optimizing opportunities for health, participation and security in order to enhance 
quality of life as people age.” 67 This concept is applicable both at the individual as 
well as at the population level. Besides health, it takes into account aspects of social 
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and environmental factors needed for active life in old age. This is an important 
paradigm, because older people estimate their quality of life differently from the 
general population, weighing besides health such parameters as social relationships 
and comparisons, dependency and material circumstances.68
Another related concept, successful aging, was introduced in the 1950’s, 
characterizing the factors and conditions fundamental for healthy aging.69  In 
1987 Rowe and Kahn 70 examined the concept of successful aging, stating that the 
modi able factors affecting the aging process, e.g. diet and exercise among other 
things, have been underestimated. A large proportion of the features of the aging 
process is attributed to lifestyle and other issues that are not due to aging itself, 
although they may increase with age.  Analogous to the WHO de nition of quality 
of life, they have later de ned successful aging as not just the absence of disease 
in old age, but it covers the mental and social aspects as well. They concluded that 
successful aging includes three major components: “low probability of disease 
or disease-related disability, high cognitive and physical functional capacity 
and active engagement with life”. 71 In this de nition, the probability of disease 
encompasses the cardiovascular risk factors present earlier in life, affecting the later 
functional capacity, which again is needed in order to successfully attend different 
activities in old age. In this sense, successful aging is highly equivalent with good 
HRQoL in old age. 
However, there are various other de nitions for successful aging.  In a review 
of larger studies, Depp et al.72 found 29 de nitions in 28 studies. Most of these 
de nitions were based on the absence of disability, omitting mental or social 
variables. 
7.2.2 COHORT STUDIES ON SUCCESSFUL AGING
Depp et al. also concluded that among the total of over 500 studies investigating 
successful aging, less than 20 have been prospective studies, thus most studies are 
restricted to survivors. This re ects the fact that although the effect of midlife risk 
factors on mortality is well known, long term studies with large numbers of long-
lived subjects and baseline lifestyle information on healthy aging are scarce. One of 
them is the Honolulu Heart Program/ Honolulu Asia Aging Study (HHP/HAAS), 
which has followed a cohort of 5.820 Japanese American men for 40 years.73 In 
this study a higher number of common modi able risk factors, such as overweight, 
smoking, excessive alcohol consumption, low physical activity, hyperglycemia and 
hypertension at the age of 55 years were inversely related to successful aging.  The 
men with no risk factors in midlife had a probability of 72% to be alive and healthy 
at the age of 75 years, whereas those with 6 or more risk factors had a probability 
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of 43% to attain this age free of de ned morbidities or physical or cognitive 
disability. The probabilities to achieve the age of 85 years healthy were 55 % and 
9%, respectively. Education level was associated with successful aging, whereas 
marital status generally did not have an impact on healthy aging in this cohort. 
Similarly, even at the age of 72 years, when selection has already occurred, the 
absence of the  ve traditional modi able risk factors (smoking, obesity, diabetes, 
hypertension and sedentary lifestyle) increased longevity and decreased morbidity 
and disability in a prospective study of healthy male physicians.74 
The data from the Cardiovascular Health Study (CHS) highlighted the signi cance 
of subclinical vascular disease in successful aging. 75 However, the many reports from 
one of the world’s longest follow-up studies on aging, the Baltimore Longitudinal 
Study of Aging (BLSA) suggest a much more complicated background:  with old 
age, there may be a dysfunction in the homeostasis of the body, making it more 
vulnerable to risk factors and subsequent disease.76
Genetic factors have been shown to in uence the human life span by 15-30% 
and this impact may accelerate after the age of 60 years.77 78
Yet, while these novel  ndings will have implications for preventive measures 
in the future, the importance of the prevention of the traditional modi able 
cardiovascular risk factors remains paramount.
7.3 COMPRESSION OF MORBIDITY
A direct extension to the concept of successful aging is the hypothesis of the 
Compression of Morbidity (COM), which was  rst presented by Fries in 1980, 79 
postulating that with preventive measures of chronic illness in the aging society, 
the postponement of death would also lead to a delay in the onset of disability.  The 
prerequisite is that the gained postponement in the onset of disability is greater 
than the delay in death, leading to a net reduction in the lifetime burden of illness.
Accordingly, this compression is expected to be greatest in preventing health 
states that do not change life-expectancy, but have an effect on disability, for instance 
osteoarthritis or Alzheimer’s disease, in contrast to the prevention of cardiovascular 
diseases or cancer, which also may lead to a decline in the mortality rates. The latter 
scenario produces a later onset of disability, but may also increase the number of 
years lived with disability, and subsequently increase the cumulative lifetime burden 
of disease and in fact lead to an expansion of morbidity in this case. Therefore, in 
order to a true compression of morbidity to happen, the prevention should lead to 
a greater postponement of the onset of disability than the postponement of death. 
Whether the prevention of major cardiovascular risk factors can lead to COM has 
not been established. Cardiovascular risk factors effect health early on in life, as in 
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the case of smoking for instance. To evaluate the impact on COM, a longitudinal 
study covering the whole lifespan is needed.
Data in the U.S. shows, that while longevity has been increasing at about 1 % 
per year, the disability rates of older adults have been declining steadily about 2% 
per year,80 indicating that at the population level morbidity and disability are being 
compressed towards the end of life. However, the scope may not be wide enough, 
neither from the individual’s point of view nor from the society’s bene t, if only 
disability is taken into account. Instead, the quality of these  nal years includes more 
than just disability, which is often equal to physical  tness. In order to fully quantify 
the bene t, the quality of these years should be measured with a valid instrument 
taking also the mental and social aspects of life into account. Besides the fact that 
living longer in good health is signi cant for the individual, the evaluation of COM 
is of crucial signi cance for the aging society, where the increasing costs of health 
care demand estimates also of the  nancial burden of disease.
7.4 CARDIOVASCULAR RISK FACTORS AND MORTALITY
7.4.1 TRENDS IN CARDIOVASCULAR MORTALITY 
Mortality due to cardiovascular diseases (CVD) and especially to coronary heart 
disease (CHD) in Finland and other developed countries underwent substantial 
changes during the 20th century. Gradually increasing to the late 1960’s, age-
adjusted death rates due to CVD were halved from 1970 to 2000 81 and the declining 
trend is still continuing.82
Despite this favorable trend, still in 2004, CVD are the leading cause of death in 
the developed countries.83 According to WHO one of every third death is caused by 
CVD, about 17 million people a year globally. Heart disease and stroke are estimated 
to become the leading cause of both death and disability worldwide by the year 
2020 with over 20 million deaths each year. 84 Almost half of all deaths in Europe 
are caused by CVD. In Finland, more than a third of total mortality was due to CHD 
or stroke among both men and women over 65 years in 2007. 85  Among men aged 
15-64  years, CHD was the second most common cause of death, accounting for 16% 
of total mortality in this age group. These  gures are higher than in most countries 
in Western Europe. While the age-adjusted cardiovascular mortality has declined, 
the total number of those with CVD has increased among older people, indicating 
that the morbidity has shifted to older age groups, especially among women.82
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7.4.2  THE CONTRIBUTION OF RISK FACTOR DECLINE TO CHD MORTALITY
The decline in mortality has in part been accomplished by major advances in modern 
medication and technology such as thrombolysis, coronary-artery bypass grafting 
(CABG), coronary angioplasty and stents, as well as ampli ed secondary prevention 
with the use of medication such as ASA, statins and ACE-inhibitors. But even greater 
an impact has been achieved by primary prevention of these diseases by means of 
changed lifestyle, diet and medication. 
Several causal risk factors of CVD have been identi ed.  Among them, high blood 
pressure, smoking, elevated cholesterol and type 2 diabetes (T2D) were individually 
the  rst four most important factors attributed to death in countries of high income 
in 2001.86 Together with alcohol  they were also the main causes for the disease 
burden as measured by disability-adjusted life years (DALYs).87 In Finland in 2007, 
al cohol-related diseases or accidental alcohol poisoning were the leading cause of 
death for both men and women in the age-group of 15 to 64 years.85 
The importance of reducing these risk factors has been shown in several 
population studies presenting declining rates of cardiovascular morbidity and 
mortality with the modi cation of risk factors. 88 89 90 In Finland, Vartiainen et 
al. 91 observed a 55% and 68% decline in coronary heart disease mortality in men 
and women, respectively, from 1972 to 1992. This was principally due to favorable 
changes in the three major risk factors, serum cholesterol, smoking and blood 
pressure during this period. Similarly, Laatikainen et al. 92 estimated that more than 
half of the decline in deaths from CHD from 1982 through 1997 in Finland may 
be attributable to reductions in major population risk factors for CHD (smoking, 
high blood pressure and elevated total cholesterol). Using U.S. data, Ford et al. 93 
determin ed that approx imately 50 % of the decline in U.S. deaths from CHD from 
1980 through 2000 may be ascribed to the positive changes in major risk factors 
and about 50 % to medical and surgical treatments for CHD, including hypertensive 
medication and primary prevention with statins.  The prospective British Regional 
Heart Study showed a 46% reduction in the incidence of myocardial infarction due 
to favorable changes in CV risk factors over the follow-up period of 25 years. The 
decline in cigarette smoking was attributed to half of this reduction.94
However, lately the prevalence of both obesity and T2D has increased and 
it is now commonly feared that this unfavorable trend may offset the bene ts 
gained from the decline of other risk factors. 95 96 Besides, cardiovascular risk 
factors are often clustered. Cardio-metabolic risk factors such as overweight or 
obesity, hyperlipidaemia, T2D, and hypertension are prone to be present in the 
same individual and result in an elevated risk of CVD and mortality. E.g. 80 % of 
hypertensive patients have other risk factors as well, and the majority of them are 
overweight. 97  Higher BMI is also associated with elevated lipid levels.98 Weight 
gain and obesity are primary causes for hyperglycemia and T2D and the metabolic 
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syndrome. 99  Furthermore, the metabolic syndrome is a multiplex risk factor for both 
CVD and T2D. 100  Also most of the patients with established CVD have multiple 
risk factors.
7.5 CARDIOVASCULAR RISK FACTORS AND COSTS
On the societal level, the direct and indirect costs for CVD are s till a major part of 
health care costs in the developed countries and they have continued to rise. In 
allocating resources in a purposeful way, an evaluation of the cost effectiveness of 
prevention of cardiovascular disease is needed. In Finland, the direct health care 
costs induced by obesity, low physical activity, smoking and alcohol were estimated 
at about one billion Euros.101 Costs associated with  subsequent diseases are partly 
overlapping, but the direct cost of diabetes alone was estimated at 500 million Euros. 
However, while a body of evidence shows the bene ts of cardiovascular risk factor 
reduction on subsequent disease, the cost effectiveness of health promotion among 
the general population in this  eld has not been studied extensively. 101 Direct costs 
on health care are only a part of the economic burden and it is more dif cult to 
evaluate the  indirect costs due for instance to work absenteeism or different aspects 
of long term geriatric care induced by cardiovascular risk factors and subsequent 
disease.   Using Medicare data in the U.S., Daviglus et al. showed that fewer midlife 
cardiovascular risk factors predicted lower heath care costs towards the end of 
life.102 Indirect costs associated with cardiovascular risk factors are already seen 
during active work age: Sullivan et al. showed that common cardiovascular risk 
factors have a harmful effect on work ability: individuals with concurrent cardio-
metabolic risk factors missed 179% more work days and spent 147% more days in 
bed (in addition to lost work days) than those without risk factors. 103   The cost of 
this loss in productivity on the U.S. economy was estimated at $17.3 billion. These 
 ndings also emphasize the importance of measuring physical disability and the 
whole HRQoL spectrum at large when the cost-effectiveness of preventive measures 
among the aging population is evaluated. 
7.6 SOCIOECONOMIC STATUS AND CARDIOVASCULAR 
 RISK FACTORS
The association between socioeconomic status (SES) and cardiovascular risk factors 
adds to the phenomenon of risk factor clustering.  Persons with lower socioeconomic 
status as determined by income, education or grade of occupation, have been shown 
to have an elevated risk of cardiovascular morbidity and mortality.104 But because 
lower SES is also associated with an increased prevalence of cardiovascular risk 
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factors, such as smoking, lower physical activity and unhealthy diet, it is unclear, 
how much these factors explain the difference in outcome. 105 This discrepancy is 
partly explained by the increased level of risk factors, but part of the mechanism is 
unknown. 106 Socioeconomic position was a strong predictor of disability in later life 
independent of a wide range of lifestyle factors and presence of diagnosed disease 
in the British Regional Heart study.107 In the prospective Women’s Health Study of 
22.688 female participants, the traditional risk factors of CVD accounted for half 
of the relationship between education and CVD risk. 108   Similarly, in a Finnish 
study risk factors related to health behavior such as smoking, low vegetable use 
and physical inactivity explained 54% of the relative difference in CVD mortality 
between the lower and higher educational level among men. 109 Behind the other 
half of this gradient there may be other factors associated with lower socioeconomic 
status. 110 For instance, the levels of psychosocial stress and social support may be 
less favorable in lower social classes. There has also been shown to be a difference 
in the access to care according to social class and income level.111  Both access and 
level of treatment and care were inferior for persons with lower socioeconomic status, 
according to a study examining the socioeconomic differences in the treatment of 
CHD in Finland.112 Also job control is associated with occupational grade, which is 
also an indicator of SES. In the Whitehall Study of 17.530 English civil servants, 
where the socioeconomic position was based on employment grade, a lower 
employment status was associated with  a 3.6 times higher coronary mortality than 
for those belonging to the professional executive grade. 113 A recent analysis of the 
Whitehall study cohort suggests that controlling for the classic cardiovascular risk 
factors would decrease the difference in mortality between socioeconomic groups 
by 69%.114  The extension of this study, the Whitehall Study II, a cross-sectional 
analysis examining the impact of SES on SF-36 scores, found a gradient according 
to SES status on all SF-36 scales except Vitality. The age-adjusted difference in the 
Physical functioning (PF) scale between the highest and the lowest employment 
grade was 6.8 points. Furthermore, the PF scale decreased with age signi cantly 
more rapidly in the low SES group among both men and women. This difference 
among men of 60-63 years was approximately 12 points between the highest and 
lowest employment grade, an effect comparable to many medical conditions. This 
association was found also among those without pre-existing disease, suggesting 
that the impact of SES on physical functioning was not solely due to different status 
of health. 115 These  ndings imply that SES may be an important source of bias in 
clinical studies. 
An association between SES and the RAND-36 scores was also detected by the 
cross sectional data combined from the Helsinki Health Study and the Whitehall 
II Study, where PCS scores were positively associated with higher education and 
occupational class. 116 
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Additionally, less prosperous socioeconomic conditions already in childhood 
may have a modest but continuing in uence on the risk of CHD in later life.117 And 
 nally, the role of persistent pathogens has recently been brought up as a possible 
explanation for the social gradient in cardiovascular morbidity. 118
7.7 GENDER AND CARDIOVASCULAR RISK FACTORS
Compared to men, women have been shown to have a more favorable pro le of major 
cardiovascular risk factors.119  Subsequently, the ave rage annual rates of  rst major 
cardiovascular events for women occur approximately 10 years later in life than for 
men, although this gap narrows with advancing age.120 In addition to differences in 
lifestyle factors, part of this difference is attributed to pre-menopausal hormonal 
in uences which exercise a protecting effect against atherosclerosis.
7.8 CHARACTERISTICS OF CARDIOVASCULAR RISK FACTORS
7.8.1  WEIGHT GAIN
7.8.1.1  Body Mass Index 
The Body mass index (BMI) is a mathematical formula that describes relative 
weight for height. It is signi cantly correlated with total body fat content. BMI is 
de ned as the individual’s body weight in kilograms divided by the square of the 
height in meters (kg/m2). Accordingly, a weight difference of 3.0 kg corresponds 
to a one-unit (kgm2) change in BMI for a man with the average height of 173 cm. 
In spite of acknowledged limitations in its ability to assess body fat regarding the 
distribution of muscle and bone mass, 121 the BMI index is considered suitable for 
distinguishing trends within overweight individuals. Since the 1980’s, the BMI has 
been endorsed by the WHO as the standard for recording obesity statistics and it is 
now the most widely used measure to diagnose obesity. 122 Overweight and obesit y 
in adults are commonly classi ed  according to the cut-off points proposed by the 
WHO: overweight is de ned as a BMI of 25.0 kg/m2 or higher, obesity as a BMI 
of 30.0 kg/m2 or higher, and extreme obesity as a BMI of 40 kg/m2 or higher. The 
concepts of overweig ht and obesity are partly overlapping, because obese persons 
are also overweight.
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7.8.1.2 Epidemiology of weight gain and obesity 
Weight gain and the subsequent obesity is a growing health problem in all developed 
countries. By 2000, the prevalence of obesity in U.S. adults was 30.5%, compared 
with 22.9% in 1994. 123  In 2004, over 70% of  American men and over 60% of women 
were overweight and 30% of both sexes were obese.124 This trend is expected to 
continue: By the year 2030, 86% of American adults are estimated to be overweight 
and 51% obese.125  In Great Britain the prevalence of obesity among adults has 
increased almost three fold from 1980 to 2002.126  A similar trend in th e obesity 
prevalence was observed during the 1980’s and 1990’s in all socioeconomic groups 
in Finland, where the proportion of obese adults had risen to 21% by the year 
2000. 127 However, according to  the latest FINRISK population survey in 2007, the 
prevalence of obesity has not risen during the last years; being 22% among adults 
aged 25-75 in 2007.128 
BMI has been shown to increase with age, 124 also in the Finnish population, 
where in addition a gradient according to the birth cohort has been shown: men 
born between 1933 and 1962 reached a BMI of 26 kgm2 before the age of 40 years, 
whereas men born in 19131922 did not attain the same BMI level until around their 
 fties. 128  As elsewhere, also in Finland the proportion of overweight individuals is 
higher in lower SES groups: Data obtained by self-report in 2004-2007, indicated 
that 65% of men in the lowest SES were overweight and 60% of men in the highest 
SES as determined by education. 129 According to measured weight among the 
participants in the FINRISK study in 2002, the gradient of BMI was approximately 
0.6 kg/m2 and 1.8 kg/m2 between the highest and lowest educated tertiles of the 
male and female populations, respectively.130
7.8.1.3 Weight gain, obesity and mortality
While the changes in treatments and risk factors during the recent decades have 
led to a reduction in cardiovascular mortality, the increased prevalence of obesity 
and the associated  rise in the prevalence of type 2 diabetes have accounted for 
an increase of deaths from coronary heart disease in 2000. 131 132 133 In the U.S., 
obesity has been estimate d to be the second leading cause of preventable death 
after smoking. 134 In 2001, about 300.000 deaths annually were associated with 
overweight and obesity. 135  
Overweight and obesity are associated with an increase in mortality from all 
causes. 136 137 138 In the Framingham Heart Study cohort,  obesity in middle age 
decreased life expectancy by 6 to 7 years compared with those with normal weight. 
139 This is similar to the risk associated with smoking. Overweight was associated 
with a 3 year reduction in life expectancy compared with normal weight individuals. 
Obese men had an 80% increase in risk of dying before age 70 years. A U.S. study 
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using the NHANES data found that obesity, but not overweight, was associated with 
an excess mortality of cardiovascular causes. 135 This may be in association with a 
recent  nding that the favorable trend of diminishing risk factors has also happened 
among the overweight and obese individuals, as obese persons now have better 
CVD risk factor pro les than their leaner counterparts did 20 to 30 years ago.140
In a Swedish study, weight gain from age 20 was associated with increased all 
cause and cardiovascular mortality, as well as increased risk of non-fatal myocardial 
infarction.141
Increased body weight has also been associated with increased mortality for 
cancers. Overweight and obesity in the United States have been estimated to account 
for 20 % of all deaths from cancer in women and 14 % in men.142 In a European 
study, excess body mass  was estimated to account for 5% of all cancers in the 
European Union.143
Although linear relationships have been observed in some studies 144 145, most 
population studies show a J-shaped association of weight and mortality.  139  146 147 
Among them, a recent European study of over 500.000 participants showed a 
J-shaped association of BMI and mortality, with the lowest risk of death observed 
at a BMI of 25.3 for men and 24.3 for women.148 After adjustment for BMI, waist 
circumference and waist-to-hip ratio were strongly associated with the risk of death. 
In a prospective study of over 1 million participants in the U.S., mortality risk 
was increased with an increasing BMI in all age groups and for both cancer and 
cardiovascular causes. 149 The lowest mortality rates were found at BMI between 
23.5 kg/m2 and 24.9 kg/m2 in men and 22.0 kg/m2 and 23.4 kg/m2 in women; 
the heaviest men and women had a 40 to 80 % increase in the risk of dying from 
cancer. Among overweight men the cardiovascular mortality was 50 % higher and 
among obese men from 60% up to 200% higher.  
7.8.1.4 Weight gain, obesity and morbidity 
Early obesity, absolute weight gain throughout adulthood, elevated BMI and waist 
circumference have all been shown to be predictors of T2D.150 151   In a study of 
middle-aged British me n, gaining weight more than 10% during a follow-up of 12 
years almost doubled the risk of T2D. 152 In addition, obesity and overweight ar e 
associated with an increased incidence of several other cardiovascular diseases and 
risk factors, such as hypertension, dyslipidemia, CHD and stroke. 153 154  155 They are 
also as sociated with several disease states such as gallbladder disease, osteoarthritis, 
sleep apnoea and respiratory problems and different types of cancer, 156 157 158 143  as 
well as overall poor health status.159  Also weight gain from age 20-29 years was 
consistently associated with elevated lipoprotein levels and blood pressure in a 
follow- up study of eight years.160 
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Although obesity is associated with increased risk of cardiovascular morbidity, 
it is unclear whether this relationship is mediated by the associated risk factors, 
especially elevated blood pressure, glucose and lipids, or whether overweight or 
weight gain independently increase the atherosclerotic burden.161 A 26-year follow- 
up of the Framingham study cohort  showed that initial body weight predicted 
the incidence of coronary heart disease and death in men independent of age and 
other risk factors including glucose intolerance. 162 Data from the Chicago Heart 
Association Detection Project in Industry (CHA) study with more than 17.000 
participants indicated that obesity in midlife was an independent risk factor for 
morbidity and mortality from T2D and CVD, when compared with those with similar 
risk factor status but normal weight.163
Also alcohol and smoking present as possible confounders when evaluating 
the impact of obesity on health. Alcohol consumption may be related to higher 
BMI.164 Smokers may have a lower BMI but a risk of higher waist circumference165 
and more CHD. Ex-smokers have a higher body weight than never smokers, as 
smoking cessation may lead to weight gain in the short term. 166 167 168 Also, obesity 
and overweight are associated with lower levels of education and lower SES,169  as 
well as low levels of leisure time physical activity.170
7.8.1.5  Weight gain and health-related quality of life 
Because overweight and obesity are linked to so many chronic conditions, the impact 
of weight itself on HRQoL has remained unclear. Large cross-sectional studies 
have shown that an increasing level of obesity is strongly associated with lower 
quality of life.171 172  They also observed a J-shaped associa tion between HRQoL and 
BMI. However, these studies were cross-sectional, and included also subjects with 
chronic conditions and diseases, which may have confounded the results.  Thus the 
association may be re ecting the effect of medical illnesses caused by excess body 
weight and not the weight per se.  Lower HRQoL seen with weight gain or obesity 
in these studies may be mediated by associated T2D or arthrosis, for example. In 
the cross-sectional study by Heo et al. of 155.989 subjects, pain appeared to be an 
important mediator in the association of HRQoL and weight. 
Longitudinal stud ies on obesity and HRQoL are scarce. In the English 
Longitudinal Study of Aging (ELSA) participants over 65 years of age were followed 
for 5 years. Those with higher BMI were more likely to develop mobility problems 
or dif culty carrying out everyday tasks.  However, excess body weight was not 
associated with greater risk of mortality in this elderly cohort. 173 Similarly, a  study 
of  Mexican Americans over 65 years showed a limitation of lower body active daily 
living (ADL) functioning for those with a weight change of over 5% during the 
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follow- up of two years.174 Yet, the potential harms of obesity in older people may 
have been underestimated.175
These studies imply that excess body weight predominantly affects the physical 
aspects of HRQOL, and not so clearly the mental domains. In addition to increased 
morbidity and functional disability, obesity could be anticipated to also affect an 
individual’s self-esteem or cause social discrimination, thus in uencing the mental 
and social aspects of HRQoL. Nevertheless, compared to the physical components 
of HRQoL, the effect of obesity on emotional well-being has been shown to be 
only modest. Besides, even this minute effect has been suggested to be due to 
comorbidity rather than obesity itself. In previous studies using the RAND-36/SF-
36 instrument, obesity has rather been associated with lower levels of the physical 
domains, such as  Physical functioning, Role physical, Vitality, Bodily pain, and 
General health than the mental domains, 176  while overweight has been associa ted 
with impaired scores for Bodily pain.177 In a cross -sectional study of 13.636 subjects 
with no chronic diseases related to obesity, the SF-12 (the shortened version of SF-
36) physical component summary (PCS) scores decreased with the increasing level 
of obesity, while the mental component (MCS) scores were lower for subjects only 
at both ends of the BMI categories.178 A study in the general Swedish population of 
5.333 subjects found that  the PCS scores of SF-36 deteriorated from 52,0 points 
for subjects with normal weight to 42,6 points for subjects with  BMI over 40 kg/
m2. 179 No change was seen in the MCS. The obese middle-aged male participants 
in this study reported signi cant impairments in the scales of Physical functioning 
and General health. However, concomitant diseases were not accounted for in this 
cross-sectional study.
In a study of Dutch individuals, using SF-36 to measure HRQoL, overweight and 
obesity were inversely related to the Physical functioning scale.180  In another cross- 
sectional study of 6.318 Taiwanese participants, only the Physical functioning scale 
was found signi cantly poorer for those with BMI 30 kg/m2 compared to non-
obese individuals. No signi cant differences were found for overweight subjects. 181 
In a cross-sectional analysis of the data of the Nurses’ Health study of 56.510 
normal and overweight women aged 45 to 71 years, the women with BMI 30 to 
35 kg/m2 reported approximately 10% lower scores (from 5.6 to 9 points) for the 
SF-36 scales of Physical functioning, Vitality and Pain compared with women with 
BMI 22 to 23.9 kg/m2. BMI was also a predictor of impaired work ability in this 
study population. 182
There are few studies on the impact of weight gain on HRQoL and they have 
mainly included obese subjects. An exception is an analysis of the data of the Nurses’ 
Health study, 183  where 40.098 women were followed for 4 years. Lean women 
who gained more than 9.0 kgs during the 4-year follow-up period experienced 
signi cant reductions in the SF-36 scales of Physical functioning, Vitality and Bodily 
pain compared with woman with stable weight, regardless of age or baseline BMI 
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levels. The decine was 6.9 points in the scale of Physical functioning compared with 
woman with stable weight. In comparison, at the same time, the respective decline 
for smoking women was 2.5 points.  
Using the data of the 6.895 male and 3.413 female British civil servants in the 
Whitehall II study, Stafford et al. 184 investigated the impact of weight gain from 
the age of 25 on for 49 years, controlling extensively for confounders. They found 
no association between weight gain and the Physical functioning score of SF-36 
in men. In contrast, women demonstrated a decline in physical HRQoL according 
to  uctuations in weight. The reason for this gender difference remained obscure.
7.8.2 CHOLESTEROL
7.8.2.1 Cholesterol levels and mortality
It is widely recognized that elevated serum total cholesterol is a major and modi able 
risk factor for cardiovascular disease. 185  In different clinical studies the relationship 
between serum cholesterol and coronary heart disease death rate has been shown to 
be continuous, graded, and strong. 186 A 1% decrease in LDL cholesterol concentration 
reduced the absolute risk of ischemic heart disease by 1-2 %,187  also in a recent meta-
analysis,188 but even stronger effects have been reported: Law et al. suggested a 30% 
reduction in ischemic heart disease at age 60, instead of 20%, for a 10% reduction 
in serum cholesterol concentration.189 In another study using data from cohort 
studies, Law et al. found that a 10 % reduction in serum cholesterol level at the age 
of 40 years reduced the relative risk for CHD by 50% at age 40, whereas the same 
10 % lowering of cholesterol begun at the age of 70 years reduced the risk only by 
20 %.190 This highlights the importance of early intervention for maximum bene t 
later in life. A meta-analysis of randomized trials of cholesterol lowering showed a 
19% reduction in coronary mortality for every 1 mmol/L of LDL lowered regardless 
of the initial lipid levels during a period of 5 years. 191 As there is no threshold in the 
relationship between serum cholesterol and CHD, the increased risk is not con ned 
to the highest levels of serum cholesterol, but in a continuously graded manner affects 
a great majority of middle-aged men in developed countries. In the Multiple Risk 
Factor Intervention Trial (MRFIT), a study of 356.222 men with 6 years of follow-
up, serum cholesterol levels 4.65 mmol/L or greater were associated with 46% of 
the excess deaths that were due to cardiovascular diseases. A recent report on the 
25-year results of the extension of the MRFIT study only con rms these  ndings. 192 
Furthermore, another recent meta-analysis 193 of  61 cohorts and 900.000 
individuals, with an average follow-up of 13 years  was on level with the  ndings 
of the MRFIT  trial; Cholesterol level was a strong predictor of CHD in all age groups 
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and regardless of other risk factors of hypertension, smoking or BMI, which the 
MRFIT data was lacking. Risk of CHD mortality was about 50 % lower for every 1 
mmol/L reduction in total cholesterol in early middle age (40-49 years) and about 
15% lower in the old age group (70-89 years). However, the absolute excess risk 
was greater with older age.
Although the Honolulu Heart Program 194 reported increased mortality for 
the pa rticipants with very low cholesterol, the suggested J-shaped association of 
cholesterol and mortality seen in cross-sectional studies has subsequently been 
suspected to be due to underlying disease. 195 196 Terminal or otherwise serious health 
 states may lead to diminished absorption or increased synthesis of cholesterol and 
thus lower serum cholesterol levels.  
During the last decades, there has been a favorable trend in the levels of serum 
cholesterol in the developed countries. In the U.S. the age-adjusted serum cholesterol 
levels among adults aged 20–74 decined from 5.74 mmol/L in 190–1962 to 5.25 
mmol/L in 1999–2002. 197  A much greater decline from 7 mmol/L to 5.3 mmol/L 
since the 1960’s has taken place in Finland.198  The latest report of the FINRISK 
2007  survey implicates that this favorable trend is continuing. However, compared 
to other industrialized countries both the serum cholesterol levels and intake of 
saturated fats are still at a higher level in the Finnish population. 199 
7.8.2.2 Cholesterol levels and health-related quality of life
The association of cholesterol levels and HRQoL have not been widely examined. 
With the prevalent use of statins in the population, examining the relationship 
between natural levels of cholesterol and HRQoL would not presently be feasible 
or ethically sound. Thus this can only be investigated in a cohort of long term 
follow-up started well before the extensive use of lipid lowering medication. Since 
the introduction and subsequent wide clinical use of statins to effectively lower 
cholesterol in patients with risk of cardiovascular disease, much interest has also 
been directed to the question whether lowering cholesterol might produce harms.
The association of cholesterol and HRQoL has mainly been studied in conjunction 
with other risk factors or in some special patient groups. A special cohort of 2.531 
participants in the Framingham Heart Study, those who survived to age 85, was 
followed from mid-age for morbidity free survival.200  The prevalence of validated 
medical outcomes, vascular diseases, dementia, and cancer were used instead of a 
HRQoL instrument to assess quality of life. Every decrease of 1 mmol/L in baseline 
cholesterol value increased the survival to age 85 free of major comorbidity by 18%.
There are hardly any studies examining the association of natural cholesterol levels 
using a validated HRQoL instrument. A cross-sectional study of 284 cardiac patients 
with dyslipidemia reported better physical health than those without dyslipidemia.201 
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A recent study of 37 Finnish patients with familial hypercholesterolemia, most 
of them with CV disease, did not show any differences for the RAND-36 scales 
compared with the general population. 202
7.8.3 ALCOHOL
7.8.3.1 Alcohol and mortality
Excessive alcohol consumption causes well-known health hazards and societal ills. 
203 As a risk factor, alcohol related diseases rank  fth on the WHO’s list of global 
burden of disease, causing 3.2% of global mortality.  87 In an  estimate by WHO for 
the year 2030, alcohol use disorders are expected to rank number four on the list of 
the leading causes for loss of DALYs (4.7% of total DALYs lost) in countries of high 
income. 204 In Finland, an alcohol-related disease or accidental alcohol poisoning 
was the leading cause of death for both working-age (ages 15 to 64 years) men and 
women in 2007. Alcohol-related causes were responsible for 18.7% in men and 
11.5% in women of all deaths in this age-group. Moreover, the number of alcohol-
related deaths increased by 8.6 % from 2006.205 
On the other hand, several studies suggest a dose-dependent, J-shaped 
relationship between alcohol consumption and cardiovascular mortality. Compared 
to abstinence or heavy drinking, favorable effects of moderate alcohol consumption 
(usually de ned as 1-2 drinks daily in men and 1 drink daily in women) especially on 
cardiovascular diseases and mortality have been documented in numerous studies. 
206  These include the prospective American Cancer Society’s Cancer Prevention 
Study I, with 18.771 deaths from coronary heart disease, 207 as well as several meta-
analyses 208 209. These studies show a consistent reduction of about 20% in mortality 
of cardiovascular causes in those participants who consume about one drink a day 
compared to abstainers.  However, this bene t has not been established in all studies. 
210 211  In the British Heart Study, 70% of middle aged non-drinking male participants 
were in fact ex-drinkers, with a high rate of obesity, smoking, hypertension and 
other illnesses. 212 Furthermore, this follow-up study found that many participants 
with a heavy drinking pattern became abstainers or rare drinkers when diagnosed 
with a heart disease or other illness during the follow-up. This  nding challenges 
the J-shape association of alcohol and mortality, as well as that of quality of life, 
and supports the sick quitter hypothesis as an explanation for the negative  ndings 
for the abstinence group. This concerns especially cross-sectional studies, but also 




At the metabolic level ethanol has been shown to have a cardio protective 
effect mediated via an increase in HDL-cholesterol and positive changes in glucose 
metabolism and hemostatic factors. 213 Drinking more than about one drink daily 
does not seem to give further protection, 214  possibly because the protective effects 
are overtaken by higher blood pressure and other negative consequences on the 
lipid and glucose metabolism 215. Moderate alcohol consumption has also been 
associated with less dementia and better cognitive function. 216 217  Consequently, 
moderate alcohol consumption could even be advocated for preventive purposes in 
middle-aged and old people. However, here too, there are opposite views, because 
observational studies cannot distinguish whether moderate drinking is associated 
with other lifestyle habits bene cial for cardiovascular health. 218 Moderate users may 
be protected by healthier diet, less smoking, better social support or better health 
status (“the healthy user bias”).219 220 Furthermore, the incidence of cardiovascular 
disease is lower in higher social classes.
Thus, although many studies have shown that moderate alcohol use has a 
bene cial effect on metabolic factors mediating CVD, and although moderate alcohol 
consumption reduces the incidence of CVD in observational studies, the fact whether 
this is a cause–effect relationship, as well as the long-term bene t of moderate 
alcohol use remain in dispute. To settle this issue, a randomized controlled trial 
would be needed. However, it would be ethically as well as technically dif cult to 
conduct such a trial with alcohol.  As it is, there are many challenges for further 
studies:  Alcohol consumption is usually a life-long habit, and the health effects 
should also be considered over the lifespan instead of a short follow-up time, and 
data of lifetime drinking habits are required.   Controlling for confounders, especially 
social class, is important in observational studies. 221 Also patterns of drinking, for 
instance binge drinking, should be recorded.
7.8.3.2 Alcohol and health-related quality of life 
In the light of the disagreement over the bene ts of moderate alcohol use, quality 
of life is a relevant addition to the endpoints for a follow-up study of overall alcohol 
effects.  For example, a 5 to 10-year postponement of coronary heart disease may not 
necessarily be worth the possible negative effects on health later on. Therefore, it is 
important to consider also other outcomes in connection with alcohol consumption. 
Despite the many effects that excessive alcohol consumption causes on 
the individual, family and society, the research on alcohol use and alcoholism 
has only recently included HRQoL as an outcome along the more traditional 
measurements.222 This is complex, because there are several factors confounding 
this association. Alcohol causes many illnesses such as cardiovascular, liver and 
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gastrointestinal diseases as well as neurological and psychiatric disturbances. 223 
It is also associated with lower socioeconomic status and further related to poorer 
work ability and problems in social life.224 Gutjahr et al. identi ed over 60 health 
consequences attributed to alcohol consumption. 225 Also smoking is more common 
among those with excessive alcohol consumption 226 contributing to the dif culty 
of determining the association of alcohol consumption and HRQoL.  
Another confounding element is that the habits of alcohol consumption vary 
from abstinence at one end to alcoholism at the other, while similar average weekly 
consumption may include different patterns of drinking such as binge drinking 
(generally de ned as consuming  ve or more alcoholic drinks on one occasion 
227) or low- to moderate dose consummated daily. This variation may depend on 
the person’s cultural background, making the interpretation of the outcomes at 
population levels further intriguing. 
The relationship between alcohol and HRQoL has mainly been studied in the  eld 
of alcohol dependency or in evaluating the treatment of alcoholism, and only few 
studies have examined the association of light or moderate use and HRQoL. HRQoL 
among alcoholics has been shown to be lower both during periods of excessive use 
and after treatment. In a study of 1.333 primary care patients Volk et al. found 
that those who ful lled the criteria for alcohol dependence scored lower points for 
all eight SF-36 scales. Patients who consumed alcohol in a frequent, low-quantity 
pattern showed better overall HRQoL than persons in other consumption groups. 228 
Using the vast cross-sectional data of the Behavioral Risk Factor Surveillance System 
(BRFSS), Okoro et al. found that frequent binge drinking (three or more times a 
month) was associated with signi cantly worse HRQOL. 229  This was consistent 
with the results of Volk et al. who reported that binge drinkers and those with a 
frequent, high-quantity drinking pattern had lower scores for the SF-36 scales of 
Role functioning and Mental health. 
In a review the HRQoL of alcohol-dependent subjects was shown to be very poor, 
but improved as a result of abstinence, controlled or minimal drinking.230 Cutting 
down alcohol consumption by 30% or more was associated with an improvement 
of 3.3 points in PCS scores compared to those with a less than 30% decrease in 
consumption during a one year follow-up. 231 In a study of twins, the alcoholic twins 
reported signi cantly lower scores for all SF-36 scales than their non-alcoholic 
counterpart twins. However, after adjusting for several confounding factors, such 
as physical and psychiatric problems, nicotine and drug dependency, marital status 
and income, only the Vitality scale of SF-36 remained signi cantly worse among 
the alcoholic twins, suggesting that the differences in HRQoL were attributed more 
to other factors than to alcohol. 232
Dawson et al. used SF-12 to analyze the changes in HRQoL of 22.245 persons with 
an alcohol use disorder during a follow-up of three years. 233 Those who developed a 
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dependency, showed signi cantly lower mental well-being, and those who reached 
remission from dependency, showed better scores as measured with the MCS of SF-
12. The results support the sick quitter hypothesis, which suggests that the abstinent 
group especially in cross-sectional studies may include persons who have stopped 
drinking due to factors that lower their quality of life. 
Nevertheless, there are studies which support a true J-shaped association 
between alcohol use and HRQoL. In a study of older patients, those who reported 
drinking alcohol, but who did not report problem drinking, had consistently better 
survival and health status as measured with SF-36 than those who did not drink 
and those who reported problem drinking.234 In a longitudinal study of 12.000 older 
Australian women, a J-shaped, dose-dependent association was found between 
physical quality of life measured with SF-36 PCS accounting for death, with non-
drinkers reporting lower physical HRQoL than moderate drinkers. 235
7.8.4 SMOKING
In 2007 in Finland, 26% of men and 17% of women aged 15-64 were smoking daily. 
236  In the age group 25 to 44 years 30% of men were smokers.  The prevalence 
decreases with age, partly because of the higher mortality of smokers and partly 
because quitting among men has increased since the 1970’s. 237 The prevalence of 
daily smokers decreases also with  increasing education. The proportion of smoking 
men was 17% in the highest educational group as opposed to 37% in the lowest. 
The difference in smoking prevalence according to educational level has broadened 
in the age group of 24-65 years in the Finnish population. 130
7.8.4.1 Smoking and mortality
Over 50 years ago, Doll et al.  rst showed that smoking can cause lung cancer. 238 
Since then, numerous studies have demonstrated the v arious ill effects that the use 
of tobacco has on health by causing especially vascular, neoplastic, and respiratory 
diseases. Smoking has a harmful effect on almost every organ in the human body 
and it is also the most powerful risk factor for atherosclerosis. 239 In men, smoking 
has been shown to shorten life by 7-10 years. 239  240  241   Worldwide, smoking is 
the second leading risk factor for all-cause death from any cause, with almost 5 
million deaths in 2000, about half of them in the developing countries. 242 In the 
U.S. smoking is the single greatest cause of preventable morbidity and mortality. 243
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7.8.4.2 Smoking and health-related quality of life 
Although previous studies have shown that a low cardiovascular risk factor pro le 
in middle age supports better HRQoL later in life,244  the effect that lifetime smoking 
per se has on the  HRQoL has not been clearly demonstrated. The problems in 
evaluating the association of smoking and HRQoL are similar to that of alc ohol. 
Smoking is linked to many confounding factors related to gender, secular lifestyle, 
education and social class. 245 In addition, for some people smoking is a life-long 
 habit, and some may quit smoking. The time since quitting is dif cult to record in 
studies, and relapses are common. Furthermore, the reasons for cessation range 
from social factors to ill health. These confounding factors may be dif cult to control 
for in studies of the general population. 
Besides the fact that smoking itself is strongly associated with several serious 
diseases, it is also linked to factors that may affect the quality of life, such as poorer 
nutrition 246 or lower socioeconomic status 247.  Thus it would be plausible that 
smoking also diminishes the health-related quality of life in the long-term. However, 
dying earlier does not necessarily mean worse HRQoL, especially during the last 
years of life. Living longer may mean more years of disability and lower HRQoL 
during the extra years gained: If non smokers live longer they also have more time 
to develop coronary heart disease or other chronic diseases causing disability and 
worse HRQoL.  At the end of their life non-smokers will have lived longer with 
cardiovascular disease.248 On the other hand, non-smokers have been shown to 
live with less disability. 249 250  Furthermore, it is also possible that smoking and 
nicotine may have some bene cial effects, such as relieving psychological stress or 
preventing Parkinson’s or Alzheimer’s disease, which may have a favorable effect 
on the quality of life of smokers.251 
The impact of smoking on HRQoL has been studied in cross-sectional studies of 
the general population, 252  253 254  which, however, cannot examine causality or ta ke 
 death into account. Shorter follow-up studies have been made in multiple disease 
states showing the bene ts of non-smoking in these subgroups. 255 256 257 
However, few prospective studies have examined the impact of long-term 
smoking on HRQoL in the old age.  An 8 year follow-up study of older people 
showed a strong relationship between smoking and worse quality of life and years of 
healthy life lost.258 Likewise, few follow-up studies have investigated the HRQoL of 
ex-smokers. Previous studies have reported improvements in HRQoL after smoking 
cessation.  A short follow-up study showed that cessation had a positive effect 
on HRQoL in nicotine-dependent smokers. 259 A 4-year follow-up demonstrated 
improvements in the  SF-36 scores of Mental health, Vitality and General health of ex-
smokers. 260 However, in a study of smokers with atherosclerotic disease, cessation 
did not show bene t on HRQoL.261 Another cross-sectional study  demonstrated 
moderate differences in smokers’ and ex-smokers’ perceived quality of life, with 
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mean differences from 3.9 points in the Physical functioning scale up to 5.3 point 
difference in the General health scale of RAND-36. 253
According to a recent  nding in the Nurses’ Health Study, PCS and MCS of SF-36 
were signi cantly lower for female smokers, compared with never- and ex-smokers. 
However, after 21 years of smoking, cessation did not bring an improvement in 
HRQoL among women.262  
7.8.5 RISK FACTOR CLUSTERING
7.8.5.1 Risk factor clustering and mortality
As cardiovascular risk factors are often present in the same individual, the overall 
risk factor status may vary from low risk to high risk. 263 In the Framingham Heart 
Study low levels of major cardiovascular risk factors in middle age were bene cial 
for overall survival and morbidity-free survival to age 85. 264 Based on the very 
large cohorts of the MRFIT study and CHA study, Stamler et al. 265 demonstrated 
that mortality was much lower for individuals with favorable levels of cholesterol 
and blood pressure, who did not smoke and did not have diabetes. For the low-
risk group of men, the life-expectancy was 9.5 years longer. Accordingly, a study of 
34.192 California Seventh-Day Adventists suggested that healthy lifestyle increased 
life expectancy up to 10 years. 266
In spite of the many methodological problems in quantifying and accurately 
relating the actual causes of deaths to modi able lifestyle factors, smoking and 
a low diet quality and sedentary lifestyle were shown to contribute to the largest 
number of deaths in the U.S. in 2000. 267
In the large Nurses’ Health Study, 55% of deaths during the 24 years of follow-
up were attributed to the combination of smoking, overweight, low physical activity, 
and poor diet.268 Similar  ndings have also been made in a smaller cohort in Europe. 
269 Bene cial levels of major cardiovascular risk factors have been shown to lower 
age-speci c mortality also in the Finnish population. 270 271  Wannamethee et al. 
investigated the association between smoking, physical activity, alcohol consumption, 
and BMI and th e likelihood of 15-year survival free of coronary heart disease, stroke, 
and diabetes in a cohort of 7.142 middle-aged men in the British Regional Heart 
Study. 272 According to the  ndings of this study, a 50-year old man, who is obese, 
smokes and has low physical activity, has only a 42% chance of surviving 15 years 
free from CVD or T2D compared with the 89% chance of a 50-year old man free 
of these risk factors.
49
7.8.5.2 Risk factor clustering and health-related quality of life
Assessment of the impact of concurrent cardiovascular risk factors on cumulative 
disability or well-being over the lifespan is dif cult because the trends in risk factors 
have been in transition. While other major risk factor levels have decreased in the 
population, the prevalence of obesity has rapidly increased. Besides, there may be 
different trends according to ethnicity or nationality. De ning the impact of different 
combinations of lifestyle factors (such as smoking or low physical activity), physical 
elements (e.g. excess body weight or hypertension) and metabolic risk factors (e.g. 
cholesterol or diabetes) is complex because there are different cause – relationships 
involved. The choice of risk factor combinations in different studies is subsequently 
diverse. Furthermore, age, socioeconomic status or educational level all may have 
a confounding effect on the results.273 
The effect of different constellations of combined lifestyle or risk factors on 
the health-related quality of life has effectively been studied only during the last 
decade. The  rst longitudinal study to examine the relation between cumulative 
disability or mortality and lifestyle factors was a study of 1.741 former university 
alumni with a follow-up from the average age of 43 years to the age of 75 years. 
274 A disability index was created by assessing eight concepts of active daily living. 
Smoking, higher BMI, and a low exercise pattern predicted mortality and initial 
disability at a younger age. The disability index for the high-risk subjects who died 
was double compared with the low-risk subjects during the last years of observation. 
The  rst study to examine the effect of cardiovascular risk factors on HRQoL in 
a broader fashion beyond physical disability, i.e. also the mental and social aspects, 
was published in 2003, when over 7.000 subjects in the large CHA study had been 
followed-up for 26 years. 245 SF-12 was used as the HRQoL instrument. Participants 
with favorable levels of all major CVD risk factors in middle age had a signi cantly 
better HRQoL and less in rmity in older age. The HRQoL decreased with the 
growing number of risk factors; the individuals with a low risk for CVD scored the 
highest points for physical, mental, social functioning and disease-free outcomes. 
In men, the largest decline was seen in the Physical functioning scale: 7-10 points 
between men with two or more CV risk factors compared with those with no risk 
factors at baseline. The differences in the Mental health scale were not statistically 
signi cant. Also the health care costs were signi cantly lower for the group free of 
CV risk factors according to an earlier analysis of the CHA study data. 275
Risk factors seem to still have an effect later in life, when selection has already 
occurred. Among the prospective cohort of the Physicians’ Health Study, 2.357 
healthy older men (average age 72 years at baseline) were assessed 16 years after 
baseline (mean age 86 years) with the PF scale of the SF-36 questionnaire to 
investigate the impact of risk factors on their functional status and well-being. 
276 The men were then followed yearly until they died or reached the age of 90, 
up to 26 years. During follow up, smoking, diabetes, obesity and hypertension 
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signi cantly reduced the lifespan. Clustering of these risk factors attenuated the 
risk. The probability of surviving from age 70 to 90 years was less than 10 % for 
those with concurrent risk factors compared to 54% for those men with no risk 
factors. Among those who lived to age 90, the low risk group scored 11.4 points 
more on the PF scale and reported 3.2 points better mental well being on the scale 
of Mental health than those with several risk factors.
7.9 PSYCHOLOGICAL WELL-BEING
Parallel to WHO’s de nition of health, 12 also mental health is more than just the 
absence of mental illness. This is pointed up in the de nition of psychological well-
being by WHO: “... a state of well-being in which the individual realizes his or her 
own abilities, can cope with the normal stresses of life, can work productively and 
fruitfully, and is able to make a contribution to his or her community”.  277 In this 
characterization the positive side of mental health, psychological well-being, is the 
basis for the individual’s successful functioning in his social environment.
7.9.1  DEPRESSION AND CARDIOVASCULAR DISEASE
While mental health is much affected by socioeconomic and environmental factors 
and is thus enhanced at the population level mainly through social interventions, 
also cardiovascular risk factors have shown to play a part in psychological health. 
There is an established link between depression and cardiovascular disease. Both 
conditions are often seen in the same patient and depressive symptoms in patients 
with cardiovascular disease have been shown to worsen their prognosis. 278 A large 
U.S. population study of eight years duration showed a 51% increased total mortality 
for persons with depression compared with those without depressive symptoms. 
Their CHD mortality was increased 1.3 to 1.5 fold, and over two-fold in depressive 
persons with diabetes. 279 During 18 years of follow-up of over 12.000 men with high 
CV risk participating in the MRFIT study, the men with the greatest depression at 
baseline had a two-fold increased risk of mortality from stroke compared to those 
with no depressive symptoms.280 In a Finnish population sample, all-case mortality 
was increased in subjects with depression, whereas an increase in cardiovascular 
endpoints was seen only in women. 281 However, the direction of causality and 
plausible mechanisms of the association between depression and cardiovascular 
disease have remained obscure. There is also only limited data proving that 
treating depression could improve cardiovascular outcomes: Medical treatment of 
depression had only a modest effect on cardiovascular outcomes in patients with 
CHD. 282 
51
The prevalence of depressive symptoms among older adults varies between 8-16 
%, while estimates of the prevalence of major depression in late-life have widely 
been around 1-4%. 283 The etiology of depression may depend upon the age o f onset. 
Vascular lesions in the brain have been suspected to be an important etiological factor 
for depression presenting later in life, and thus also the clinical symptoms m ay be 
different between early-onset and late-onset depression. 284Although depression is 
less frequent in old age than earlier in life, depression is a signi cant factor affecting 
the HRQoL of older people. In a cross -sectional study, depressed participants over 
60 years of age showed signi cantly lower scores for  ve of the eight SF-36 scales 
(General health, Mental health, Role emotional, Social functioning and Vitality) 
compared with norms for older individuals. 285 Several studies have also found a 
link between depression and physical functioning. In a follow-up study of four years’ 
duration of older participants, depressive symptoms predicted a decline in measured 
physical performance. 286 However, even in longitudinal studies the direction  of 
causality is not clear for the functional decline seen in depressive patients, because 
disability may induce depression and on the other hand, depressed participants may 
repor t their physical functioning lower than non-depressive controls. 283
7.9.2  POSITIVE HEALTH STATES
There has been growing clinical and research interest in positive psychological 
well-being, because positive feeling states appear to have consequences that are 
independent of negative states.  287 The distinction between negative and positive 
affect was  rst introduced by Bradburn in 1969.  288 He concluded that an individual’s 
psychological well-being depends on the independent dimensions of positive and 
negative affect. According to this de nition, positive affect is not simply the opposite 
of negative feeling state. 
Because psychological well-being depends besides health on many genetic, 
social and economic factors, there are consequently many variables attached to 
the concept of positive affect. 289 Among the positive feeling states, happiness and 
life satisfaction have been identi ed as central indicators of psychological well-being 
and functioning. 9 However, these concepts are loosely de ned and are often seen 
to be used interchangeably with subjective well-being in the medical literature. 
Positive states are also related to physical health:  Positive affect has been 
associated with fewer strokes, 290 life satisfaction was related to long-term mortality 
among healthy adults,291 and positive life orientation predicted subsequent survival 
in old people 292. The processes that underlie these effects are not clear. Positive 
 emotions may be a life-long trait and promote a health-conscious lifestyle. 
Furthermore, a study showed that positive affect in middle-aged individuals was 
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directly related to biological processes (cortisol output, heart rate and  brinogen 
stress response) associated with bene cial health effects. 293 On the other hand, 
positive affect may also be modulated during the life course. Nevertheless, as part of 
mental health, positive emotional states are related to a key dimension in HRQoL. 
Subsequently increasing happiness among the growing geriatric population has 
been identi ed as an important aim in public policy. 87
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8 AIMS OF THE PRESENT STUDY
These studies were performed to examine the impact of major modifiable 
cardiovascular risk factors (weight gain, cholesterol, alcohol consumption, smoking 
and combined risk factor status) present in middle age on the health related quality 
of life in old age, with account for mortality and several confounding factors among 
the cohort of the Helsinki Businessmen Study. 
I  The aim of substudy I was to investigate whether gaining weight since the age 
of 25 years to middle age predicts health-related quality of life in old age.
II  The aim of substudy II was to examine how the amount of alcohol consumed 
in middle age affects the health-related quality of life in old age, with mortality 
taken into account.
III Substudy III aimed to study the effect of serum cholesterol in middle age on 
the HRQoL in old age.
IV The effect of cigarette smoking in midlife on the HRQoL in old age was 
investigated in substudy IV.
V  In substudy V clustering of cardiovascular risk factors was identi ed in the 
cohort in middle age to investigate their in uence on HRQoL later in life.
VI Substudy VI aimed to further examine how cardiovascular risk of men in 
midlife is associated with mental aspects of HRQoL, speci cally the negative 
and positive affect in old age.
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9 DATA AND METHODS 
9.1 THE HELSINKI BUSINESSMEN STUDY 
The current thesis project is part of a prospective study called the Helsinki 
Businessmen Study. The data gathered from the participants who took part in the 
examinations between 1964-1973 (median year 1968) offer the basis for the studies 
presented in this thesis. The schedule of the Helsinki Businessmen Study from the 
1960’s to 2003 is presented in Figure 1. A more detailed timeline for the study is 
summarized in Appendix C.
  Since the data for cardiovascular risk factors has been collected at different time 
points and as the availability of data is different for each risk factor, the follow-up 
time for the impact of individual cardiovascular risk factors varies, as outlined for 
the respective substudies in Table 7. 
Figure 1. Timeline of the Helsinki Businessmen Study
1964-1973 Voluntary health examinations performed at the Institute of Occupational Health in Helsinki for 3.490 men in leading positions 
1974 Baseline examinations for 2.375 men.  Among them, identifi cation of low (593 men) and high (1.222 men) cardiovascular risk groups. 
1974-1980 1.222 healthy men of the high cardiovascular risk group participated in an intervention study from 1974 to 1980. 
1986 Mailed questionnaire sent to 1.723 men. Clinical examinations in 1.399 men. 
1990’s Mortality and morbidity retrieved from registers at several time points. 
2000
Mailed questionnaire including the RAND-36 health-related quality 
of life survey available for 1.864 men. Mortality retrieved from 
national registers. 








9.2 BASELINE EXAMINATIONS IN 1964-1973
Since 1964 the Institution of Occupational Health in Helsinki performed voluntary 
health examinations aimed at men in leading job positions. Up to the year 1973, 
3.490 men took part in these examinations, which were then repeated with intervals 
from 2 to 5 years. At that time occupational health care was not customary in Finnish 
companies. The men were mostly business executives or managers in different 
companies mainly in the  eld of industry or commerce. They were born in 1919-
1934, and the mean age in 1974 was 47.8 years (SD 4 years). The constitution of 
these health checks are presented in Table 1.
Table 1. The composition of the health evaluations performed between 1964 and 1973 (median 
year 1968):
Assessment Contents
Clinical examination ● performed by a physician
● height and weight measured
● blood pressure
● smoking status
Laboratory examinations ● serum cholesterol
● serum triglycerides (from 1969 onwards)
● blood glucose one hour after a glucose load (1 g/kg 
● of body weight of glucose orally)
Of the original examinations of 3.490 men, risk factor levels are available for 
3.313 men, 95% of the original study population. 
This cohort was not originally created for scienti c purposes, but it was later 
discovered that the socioeconomic similarity of the participants offers an appropriate 
basis for evaluating the signi cance of cardiovascular risk factors on subsequent 
health status. Consequently some observational studies have been performed using 
the data gathered from this cohort.  
9.3 BASELINE EXAMINATIONS IN 1974 IN GENERAL 
 (MIDLIFE EXAMINATION)
The  rst scienti c investigation of this cohort was performed in 1974, when 
associations between baseline electrocardiographic  ndings and cardiovascular 
risk factors and coronary heart disease were examined in 2.821 participants. 294 
In 1973-1975 (mainly in 1974) the men were approached in order to  nd healthy 
participants with cardiovascular risk factors for a primary prevention study.  A 
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mailed questionnaire and an invitation to have laboratory samples and an ECG 
taken were sent to all men who had participated in the health examinations since 
1964. The contents of the questionnaire in 1974 are presented in Table 2.
Table 2. The composition of the questionnaire in 1974.
Past and current diseases and medication  
Cardiovascular risk factors and lifestyle  
● Smoking status 
● never smoker/ex-smoker/current smoker
● number of cigarettes smoked/day 
● use of cigar/pipe 
● Alcohol consumption
  ● preference: beer, wine or liquor 
  ● consumption/week
● Self-reported current health and physical fi tness 
   ● 5-step scale: ”very good”, ”good”, ”fair”, ”poor”, ”very poor” 
Based on the self-reported questionnaire, the presence of chronic diseases, 
regular use of medication, abnormal laboratory results and ECG  ndings were 
used as exclusion criteria for the primary prevention study (Table 3).
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Table 3. Exclusion criteria for the primary prevention study in 1974.
Hypertension ● SBP  200 mm Hg and/or DBP 115 mm Hg (values 
 exceeded both in the self reported questionnaire and 
 at clinical examination). 
● medication for hypertension
● secondary hypertension
Cardiovascular disease ● History of myocardial infarction 
● Angina pectoris according to the Rose questionnaire295 
● ECG changes, classifi ed according to the criteria 
 defi ned by the Minnesota Code 296 :
   ● CHD
   ● Conduction abnormalities
   ● Cardiac arrhythmia, disturbances of cardiac rhythm
● History of or clinical cardiomyopathy
● History of valvular disease, III-IV degree systolic 
 murmur or diastolic murmur on clinical examination
● Heart failure: treated or clinically present
Cerebrovascular disease ● History of TIA or stroke (cerebral hemorrhage or 
 ischemic stroke)
● Unilateral symptoms or fi ndings of hemiparesis on 
 clinical examination
Diseases of the kidneys ● Renal failure (S-creatinine  150 umol/L)
● Renal disease: proteinuria, pathological fi ndings in 
 sediment or urography
Metabolic diseases ● Medical treatment for diabetes
● Uncontrolled diabetes (fasting blood glucose  10 
 mmol/L)
● Medical treatment for hyperlipidemia




Of the original cohort, 68 men had died before 1974. Furthermore, 867 did 
not respond or refused to take part in the study. Subsequently, according to the 
medical history and cardiovascular risk pro le presented by the results of these 
questionnaires and laboratory and ECG  ndings, the cohort could then be divided 
into 5 groups: 
1) Men who reported to be healthy, with no cardiovascular risk factors above the 
prede ned levels and no symptoms or signs of cardiovascular disease (= the 
low risk group, n=593). 
2) Men who reported to be healthy, but had at least one prede ned cardiovascular 
risk factor (= the high risk group, n=1.222). 
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3) Those with known chronic disease or medication as described above (n= 563)
4) Those who refused or data is otherwise not available (n=867) 
5) Dead (n=68)
 
The group of the 1.222 men who were healthy and who had at least one 
cardiovascular risk factor, was then divided into two groups for an intervention 
trial to investigate the effect of intensive treatment of cardiovascular risk factors in 
612 men, compared to a control cohort of 610 men who did not receive any special 
action for their risk factors. For this purpose, a clinical examination was performed 
on all 1.222 participants and this included the procedures presented in Table 4.
Table 4. Measurements for the 1.222 men, who were healthy, but had at least one cardiovascular 
risk factor in 1974. 
Variable Measurement
Blood pressure measured with a mercury sphygmomanometer in 
the sitting position after a 10-min rest. 
Heart rate calculated from the resting ECG
Cholesterol  and triglycerides measured by standard methods in the fasting state
Blood glucose measured in the fasting state and one hour after 
a glucose load (1 g/kg of body weight of glucose 
orally). 
Smoking status determined on the basis of a self-reported 
questionnaire (number of cigarettes/day)
Alcohol consumption assessed with a self-reported questionnaire (beer, 
wine, and liquor separately), calculated as grams of 
ethanol per week.
Weigh measured. *
* In 1974, relative body weight (%) calculated as body weight (kg) * 100 divided by height (cm) 
minus 105), was used to characterize overweight. However, body mass index (BMI), calculated 
as weight (kg) divided by height (meters) squared was used in the subsequent analyses. 
The results of this intervention trial from 1974 to 1980 were published in 1981 
and 1985. 297 298 
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9.4 EXAMINATIONS IN 1986
A third scienti c evaluation was performe d in 1986, when the changes in the risk 
factors during follow-up were recorded and t he effect of the intervention program 
from 1974 to 1980, six years after the  nal visits was re-evaluated.299  For this a 
mailed questionnaire was sent to those participants (n= 1.723) who were healthy 
in 1974 and alive in 1986. 1.399 men (82%) replied, although the responses to 
the questionnaire were not all complete. Smoking status and alcohol consumption 
were assessed by the questionnaire. The men were also asked to have their blood 
pressure, weight and waist circumference measured, as well as blood samples and 
ECG taken at their local health care provider. Cholesterol values were gathered 
in 1.246 (73%) men, HDL- cholesterol in 1.241, triglyceride in 1.236 and glucose 
values in 1.215 participants.  
9.5 FOLLOW-UP OF MORTALITY AND MORBIDITY 
 DURING THE 1990’S
Mortality and morbidity of the initial cohort and the groups which were identi ed 
in 1974 have been followed up using national registers during the 1990’s. These 
results have been published previously. 300 301 302 
9.6 THE 2000 SURVEY (LATE-LIFE EXAMINATION)
In 2000, a mailed questionnaire was sent to all 2.286 survivors of the original cohort 
of 3.490 men, re-mailed once for non-respondents and 1.864 (88%) responded. 
The questionnaire included the variables presented in Table 5.
Table 5. The composition of the questionnaire in 2000
  
● current diseases including cardiovascular diseases and diabetes 
● alcohol consumption 
● physical activity
● weight
● the latest measured BP value
● current smoking status 
● the Finnish version of the RAND-36-Item Health Survey 1.0 
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Because a substantial proportion of men had died by the time of the RAND-36 
evaluation in 2000, the technique described by Diehr et al. 66  to account for deaths 
when assessing health-related quality of life was used for substudy III. This technique 
produces logistic regression coef cients to derive new PCS and MCS values which 
account for death and estimate the probability of being healthy in the future. Being 
“healthy” is de ned as being in the top 75% of the reference population for the 
PCS and MCS. Death is coded as zero. This method was employed to obtain the 
transformed PCS and MCS values presented in the substudy III of this thesis.
The summary measures of RAND-36 have not been validated in the Finnish 
population. Therefore, the general 1998 U.S. population norms are used as reference 
for the PCS and MCS scores in the substudies of this thesis.  
9.7 THE 2002-2003 SURVEY OF NEGATIVE AND 
 POSITIVE AFFECT 
In 2002-2003, another mailed questionnaire survey was sent to the surviving 
participants (n=872) (re-mailed once for non-respondents) and at this point 73% 
(n=633) responded. The questionnaire included partly the same items as the 2000 
survey (symptoms and diseases, current medications, present weight). In addition 
there were also several questions about attitudes towards life.
Table 6. The composition of the 2002-2003 questionnaire of negative and positive aff ect 
(response categories are presented in parenthesis).
● Are you satisfi ed with your life? (yes/no), 
● Do you have zest for life?(yes/no), 
● Do you feel needed? (yes/no), 
● Do you have plans for the future? (yes/no), 
● Do you suffer from loneliness? (seldom or never/sometimes /often or always), 
● Do you feel yourself depressed (seldom or never/sometimes /often or always). 
Positive life orientation was regarded to be present if the participant answered 
“yes” or “seldom or never” to these six questions. These domains have been suggested 
to be major components of psychological well-being among older people. 8 303 This 
questionnaire has been used in a previous study, where positive life orientation 
was shown to predict mortality in older people. 293 These questions have also been 
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shown to have good concurrent validity with the RAND-36 questionnaire. 304
The participants were also asked to rate their whole life course (life experiences, 
fullness of life, ingredients) using the Finnish school marks from 4 (worst) to 10 
(best). Visual analogue scales (VAS; 10 cm) were used to assess present global 
happiness (0=very unhappy, 10=very happy). 
Negative affect was further assessed with the Zung self-rating depression scale19, 
a widely used instrument in epidemiological studies, embedded in the questionnaire. 
It consists of 20 items which were coded into a score as instructed.  A person with 
a Zung score below 50 points was considered normal, with a score of 50-59 was 
considered to suffer from mild depression and a score of 60-69 was considered to 
suffer from moderate to marked depression. 
9.8 MORTALITY FOLLOW-UP
Total mortality of the study population was retrieved from the National Population 
Information System of the Finnish Population Register Centre, which keeps registry 
of all Finnish citizens through 2000 and up to 31 December 2002. According to the 
Centre, assessment of vital status is very reliable for people having their permanent 
place of residence in Finland (over 95% of the present cohort in 2000) irrespective 
whether they die in Finland or abroad. Also, the assessment of the vital status for 
the Finnish citizens living permanently abroad is quite reliable.  
9.9 ETHICAL CONSIDERATIONS 
The follow-up study has been approved by the Ethical Committee of the Department 
of Medicine of the Helsinki University Hospital.
9.10 STATISTICAL METHODS
NCSS software was used for the analyses (NCSS Statistical Software, Kaysville, 
UT; Internet: www.ncss.com). In statistical analyses two-tailed tests were used 
and P values < 0.05 were considered as signi cant. Descriptive statistics, T-tests, 
nonparametric tests, and analyses of covariance (ANCOVA) were used to compare 
continuous variables. Chi-square and trend tests were used to compare proportions, 
and Spearman rank coef cients to assess correlations. Differences in survival 
were analyzed using Kaplan-Meier curves and log-rank tests. Relative risks (RR) 
with their 95% con dence intervals (CI) for mortality were calculated using Cox’s 
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proportional hazards regression. The assumptions for proportional hazards were 
tested where appropriate. Other risk factors were adjusted for in respective models. 
The eight RAND-36 scales were constructed as instructed. 40 The physical component 
summary (PCS) and the mental component summary (MCS) scores were calculated 
of the eight RAND-36 scales as instructed. 45 
9.11 THE CHARACTERISTICS OF INDIVIDUAL RISK FACTORS  
 DURING FOLLOW-UP
Due to missing data, the number of participants in the substudy analysis for different 
risk factors varies.  Besides, there were some differences in the baseline variables 
and protocol of each substudy. These characteristics are outlined in Table 7.
Table 7. The number of men for whom risk factor data were available at baseline and during 
follow-up in each substudy. The number of men in the original cohort in 1964-1973 is 3.490 
men. The numbers during follow-up diff er due to missing data and diff erences in  substudy 














1974 1.657 2.245 1.808 1.658 1.203
1980 1.654










years 26 39 29 26 26-28
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9.11.1 STUDY I: WEIGHT GAIN
For this substudy, the impact of weight gain on mortality and HRQoL was examined 
in 2.206 men, who in 1974 recalled their weight at 25 years of age.  In closer 
examinations, 549 were found to have a history or signs of chronic diseases or 
medication and were excluded from the analyses. In 1974 weight and height were 
measured and the BMI was calculated. The change in body weight during early 
midlife was calculated as weight in 1974 (average age 47 years) minus weight at the 
age of 25. According to this change in body weight the men were then categorized 
into quartiles as outlined in Table 8. The quartiles were used in the further analyses 
of the effects of weight change.  Because weight loss may indicate subclinical disease, 
the lowest quartile was further divided into those who did not gain weight and 
those whose weight increased less than 4.1 kg, and thus the analyses include  ve 
weight change groups.
Table 8. Classification of the change of body weight from age 25 to 1974 in the 
study population (n=1.657). The lowest quartile is further divided into those who 
did not gain weight (1a) and those whose weight increased less than 4.1 kg (1b).
Quartile Number of men Change of body weight, kg
1a 188 Loss or no gain
1b 244 0.1 to 4.0
2 415 4.1 to 9.0
3 385 9.1 to 14.9
4 425  15.0
Data on weight are subsequently available at several time points. The weight 
of 1.275 men (82% of survivors) was later measured in 1986 when they were re-
assessed also with questionnaires and laboratory examinations. 
In 2000 the mailed survey was sent to survivors (n=1.265), self reported weight 
and responses for the RAND-36 questionnaire are available for 1.147 (90.7 %) 
men. The analysis was adjusted to covariates (age, smoking, alcohol consumption, 
subjective health and physical  tness in 1974, body weight at 25 years and at year 
2000) which were not considered to be in the pathogenetic pathway between weight 
gain and clinical end points. The total mean follow-up time is 26 years. 
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9.11.2 STUDY II: CHOLESTEROL
This substudy on the associations of cholesterol, mortality and HRQoL includes 
the 3.277 men (94 % of the total cohort) for whom baseline serum cholesterol 
measurements were available in 1964-1973. Follow-up examinations were made 
in 1974, 1985-6 and 2000. Total follow-up time is up to 39 years. The follow-up 
data are comprehensive at baseline and at the end, whereas the three in-between 
evaluations include only part of the study population. During follow-up, fasting 
serum cholesterol was measured in 1974 in 2.245 men and in 1985-6 in 1.246 men. 
In 2000 cholesterol values were based on self-report by 1.292 (71%) men. 
For the measurements in 1964-73 and 1974, serum cholesterol concentration 
was determined using the method of Huang et al.305 Since then routine laboratory 
analyses were performed using enzymatic methods, which yield lower values. 
Hence, corrected values have been used for the present analyses; the conclusions 
nevertheless remained the same when original values were used. For the survival 
analyses the results are presented in two fashions:  
1) According to the baseline cholesterol values divided into per 1 mmol/L increasing 
groups as follows:
● 5.0 mmol/L (n = 224), 
● 5.1 to 6.0 mmol/L (n = 803), 
● 6.1 to 7.0 mmol/L (n = 1.170), 
● 7.1 to 8.0 mmol/L (n = 720), 
● 8.1 to 9.0 mmol/L (n = 255), 
● and >9.0 mmol/L (n = 105),  
2) Comparing the lowest cholesterol group (5.0 mmol/L, n =224) with other 
groups combined. 
This second method was used for the HRQoL analyses. The RAND-36 scores 
were available for 1.820 of the 2.251 surviving men (80.9%) in 2000. 
9.11.3 STUDY III: ALCOHOL
The impact of alcohol consumption in midlife in 1974 on mortality and HRQoL in 
old age in 2000 was analyzed for this study.  The total mean follow-up time is 29 
years.  At baseline in 1974 detailed alcohol consumption data was collected with a 
questionnaire for 1.808 men, when they were asked to report their weekly alcohol 
consumption (beer, wine, and liquor separately) during the past year.  One unit 
of alcohol (”a restaurant unit”: a bottle of beer, a glass of wine, a single drink of 
spirits) was calculated to contain 14 grams of pure alcohol. The alcohol intake was 
summed up to produce an approximation of total consumption as grams of ethanol 
consumed per week. The consumption at baseline (grams/week) was divided in 
three categories: 
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1) zero consumption (n=116)
2 moderate consumption (1 to 349 g of pure alcohol per week, mean consumption 
less than 3 drinks/day, n=1.519)
3) high consumption (350 g/week or more, mean consumption 5 drinks/day, 
n=173)
Of the initial 1.808 men, 1.654 men were re-examined in 1980, and 1.275 (82% 
of survivors) could be re-assessed in 1985-86 with questionnaires and laboratory 
examinations. This survey included the same question about alcohol consumption 
as at baseline. Serum gamma-glutamyl transferase activity was measured in 235 
men and this information was used to validate the reported alcohol consumption. 
In 2000, 1.216 (86%) of 1.416 surviving participants responded to the mailed 
questionnaire and the RAND-36 scores were calculated. The question on alcohol 
consumption in the 2000 survey was similar to the earlier surveys of 1974 and 
1986. Baseline alcohol consumption was not different between respondents and 
non-respondents.
9.11.4 STUDY IV: SMOKING
For this study the impact of smoking status in 1974 on mortality and HRQoL in 
2000 was analyzed, with a mean follow-up time of 26 years. Smoking status was 
collected with a questionnaire for 2.464 men at baseline in 1974. The 581 men who 
had any chronic disease or medication were excluded from the analysis, as well as 
those 160 men who reported smoking cigars or pipe. The smoking status was not 
available for 5 men.  The 1.658 men in the substudy cohort were classi ed into four 
groups according to their reported smoking status in 1974: 
1) never-smokers (n=614), men who had never smoked and were not currently 
smoking, 
2) ex-smokers (n=650), those who had been smokers before, but had quitted 
smoking by 1974, 
3) 1-10 cigarettes /day (n=87), those who were smoking 1-10 cigarettes daily, 
4) 11-20 cigarettes/day (n=119), 
5) over 20 cigarettes /day (n=188). 
The duration of the smoking habit or the length of cessation of smoking before 
1974 was not recorded.
In 2000, the smoking status and RAND-36 scores were assessed in 1.131 men 
(88, 0%) of the total cohort of 1.286 men alive.
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9.11.5 STUDY V: CARDIOVASCULAR RISK PROFILE
For this substudy the relationship between total cardiovascular risk in midlife and 
HRQoL and mortality in old age was examined by comparing men with a low risk 
factor status with men with risk factor clustering at baseline. From the original cohort 
of 3.490 participants, the men who had any chronic disease or medication were 
excluded, and among the healthy participants, two groups of 593 men with low and 
610 men with high levels of risk factors were identi ed in 1974. Both groups acted 
as the usual care groups in the multifactorial intervention trial described above. 299 
In order to be rated at high risk, at least one of the six risk factors listed in Table 
9 had to be present on two occasions (except elevated one-hour glucose only once) 
at baseline; otherwise, the classi cation was low risk.
Table 9. The levels of the predefi ned risk factors that were employed to identify the 610 men 
in the high risk group in the subcohort of 1.222 healthy men in 1974.
● Relative body weight  120%, corresponding to BMI of 27.8 kg/m2 
● Smoking > 10 cigarettes/day
● Systolic and diastolic blood pressure 160/95 mm Hg 
● Serum cholesterol 7.0 mmol/L 
● Serum triglycerides 1.7 mmol/L 
● One-hour post-load glucose value  9.0 mmol/L. 
All the men in the high-risk group attended a check-up on two occasions, but 
those men with none of the risk factors on the  rst occasion did not necessarily 
proceed to second measurements. The exact proportion of these men is not available 
in the present database.  The average number of risk factors in the high-risk group 
was 2.1.
 In the 2000 query responses including the RAND-36 questionnaire were 
gathered from 448 participants in the baseline low-risk group and from 407 in 
the high-risk group of the total cohort of men alive. Response rates were 90.7% 
and 88.5%, respectively. Total time of follow-up was 26 years.
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9.11.6 STUDY VI: PSYCHOLOGICAL WELL-BEING
The data of the two groups of healthy men (593 men with low and 610 men with 
high levels of prede ned risk factors), which were identi ed in 1974 and employed 
for substudy V, were also used for this substudy examining the impact of midlife 
cardiovascular risk factors on psychological well being in old age. For this substudy, 
mortality was available through December 31st 2002. In 2002-2003 a questionnaire 
was sent to all survivors. Depression was evaluated with the Zung self-rating 
depression scale 19  and positive affect was assessed with the six self rated questions 
as described in detail above. The response rate was 74% (n=336) and 71% (n=297) 
in the low and high risk groups, respectively (P=0.4).The average age of responders 




10.2  WEIGHT GAIN
10.1.1 BASELINE CHARACTERISTICS 
For substudy I, the effect of weight gain on mortality and HRQoL was examined 
in 1.657 men.
At baseline in 1974, the mean age of the cohort was 47 years, SD 4 years.  The 
mean BMI at the age of 25 was 22.7 kg/m2 and 25.8 kg/m2 in 1974, denoting an 
increase from the mean weight of 71.2 to 81.0 kgs. 14.7 % were smokers. Mean 
alcohol consumption was 121.9 g/week.  
10.1.2 THE DEVELOPMENT OF WEIGHT OVER THE STUDY PERIOD
Lifetime changes in body weight are shown in Figure 2. 




























Weight increased from 25 years of age until midlife, but not thereafter. Less than 
1% (n=11) of this cohort had BMI > 30 kg/m2 at 25 years, compared to 7.2% (n=120) 
in 1974.  Mean BMIs (SD) were 22.7 kg/m2 (SD 2.1), 25.8 kg/m2 (2.7), 26.1 kg/m2 
(3.0), and 25.8 kg/m2 (3.1), at 25 years, 1974, 1986 and 2000, respectively.  Mean 
weight gain from the age of 25 years until 1974 was 9.8 kg (SD 8.3) and the gain 
was signi cantly inversely correlated with weight at 25 years  (r= -0.305, P<0.0001). 
10.1.3  MORTALITY DURING FOLLOW-UP
The average age among survivors in this substudy was 73 years (SD 4). Through 
December 31, 2000, 392 (23.5%) men had died. Weight at 25 years of age did not 
predict mortality. Mortality was similar in the lower weight gain groups, but was 
signi cantly higher (29.8%) in the highest quartile of weight gain of 15.0 kg. There 
was no signi cant over-mortality (23.3%) among those who did not report weight 
gain during midlife. (Figure 2.)  
Figure 3. Mortality (%) according to the weight gain from 25 years of age until 1974, when 














The relationship between mortality and weight gain was further analyzed 
adjusted for age, body weight at 25 years, smoking, alcohol consumption, subjective 
health and physical  tness in 1974. The highest quartile of weight gain was associated 
with 39% increased total mortality vs. lower quartiles (OR 1.39, 95% CI 1.12 to 1.73) 
in these analyzes. 
10.1.4  HEALTH-RELATED QUALITY OF LIFE IN 2000
In the 2000 survey, scores for the RAND-36 scales did not signi cantly differentiate 
for the quartiles of body weight at age 25. According to weight quartiles in 2000, 
signi cant and inverse patterns with increasing weight were observed in the scores of 
Physical functioning, Role limitations due to physical problems and Role limitations 
due to mental problems. The differences seen in other scales of RAND-36 were not 
statistically signi cant.  In contrast, there were clear differences in all the scales 
according to the quartiles of midlife weight gain (Figure 4.), when the scales were 
adjusted for age, weight at age 25 and in 2000, smoking and alcohol consumption, 
subjective health and physical  tness in 1974. In seven out the eight RAND-36 scales 
the differences were statistically signi cant between the weight gain groups. Men 
with no weight gain in midlife had consistently the best quality of life.
Figure 4.  Weight gain (kgs) in midlife and quality of life (RAND-36) in old age in 2000  
 
Abbreviations (and global P values) for the individual  scales: PF= Physical functioning (P=0.002), 




























General health (P=0.02), VT= Energy/vitality (P<0.001), SF= Social functioning (P=0.02), RE= 
Role limitations due to problems of  mental health (P=0.006), MH= Mental health/emotional 
well-being (P=0.06).
In all scales the scores were adjusted for age, smoking, alcohol consumption, subjective health 
and physical fi tness in 1974, and body weight at age 25 and in 2000.
10.2 CHOLESTEROL 
10.2.1 BASELINE CHARACTERISTICS  
At baseline of this substudy, the average age of the cohort (n=3.277) was 38 years 
(SD 4). 224 men (6.8% of all) had serum cholesterol values of 5.0 mmol/L or lower. 
Nearly half of the men (44.9%) were smokers. 
In 1974, the distributions of subjective health and physical  tness did not differ 
between the low cholesterol group and other groups combined: the P-values for 
the overall differences between the groups were 0.37 (subjective health) and 0.75 
(physical  tness). Only 6.3% and 6.6% of the men in the lowest cholesterol group 
and others, respectively, reported their subjective health as “poor” or “very poor”. 
The respective proportions for physical  tness were 14.9% and 16.2%.  
10.2.2 THE DEVELOPMENT OF CHOLESTEROL LEVELS OVER THE  
 STUDY PERIOD
Cholesterol values tracked quite well during the long follow-up.   Those alive in 2000 
(n=1.292) reported their latest serum cholesterol value in the 2000 survey showing 
that baseline differences of cholesterol values had basically stayed the same over the 
years, with a general regression to the mean, except in the lowest cholesterol group, 
where there was no apparent change from baseline. 16% of responders reported 
using cholesterol lowering medication in 2000.
10.2.3 MORTALITY DURING FOLLOW-UP
After a follow-up period of 39 years, 1.173 deaths (35.8% of all) from all causes 
occurred. Total 39-year mortality increased in a graded manner according to the 
baseline serum cholesterol level (Table 10.). Survival curves of the lowest cholesterol 
group (5.0 mmol/L) vs. other groups combined are shown in Figure 5. 
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Figure 5.  Survival curves of lowest baseline cholesterol group (5.0 mmol/L, n=224) vs. 
higher cholesterol group (>5.0 mmol/L, n=3.053). P-values between groups were determined 
with log rank tests. (P= 0.003)
 
The curves demonstrate that the survival bene t in the lowest cholesterol group 
was even accentuated during the last years of the follow-up.
As indicated in Table 10, multivariate analyses showed that the relative hazard of 
death rose by 11% (95% CI 6% to 17%) for every increase of 1 mmol/L of cholesterol 
(adjusted for age, body mass index and the year of  rst cholesterol measurement). 















Table 10. Multivariate relative risk (RR) of 39-year mortality according to baseline cholesterol 
in the total cohort (n=3.277)  
Baseline cholesterol Risk ratio of mortality*









 5.0 mmol/L (n=224) 








*Risk ratio calculated using the Cox proportional hazards model (with 95 % CI) 
Model A: adjusted for age
Model B: adjusted for age, BMI, and the year of fi rst cholesterol measurement
Model C: adjusted for age, BMI, smoking, systolic blood pressure, one-hour glucose (log trans-
formed), and the year of fi rst cholesterol measurement
10.2.4 HEALTH-RELATED QUALITY OF LIFE IN 2000
The response rate to the 2000 survey was 81% (n=1.820). Average age of respondents 
was 73 years (SD 4). Age and baseline cholesterol concentrations were identical 
in respondents and non-respondents. The Physical component summary score 
PCS  (adjusted for blood pressure, BMI, baseline smoking, and age) showed a 
markedly better physical quality of life score in the group with the lowest baseline 
cholesterol level  (5.0 mmol/L, n=224 )  compared with the combined higher-
cholesterol group ( >5.0 mmol/L, n=3.053): 47.6 points versus 45.4 points (P = 0.02) 
(Figure 6). Of the individual RAND-36 scales, Physical functioning and Bodily pain 
were signi cantly better by 7.8 and 6.4 points, respectively, for the lowest baseline 
cholesterol group (Figure 7). The differences between the RAND-36 scales denoting 
mental heath were not statistically signi cant, and  there was no difference in the 
mental component score MCS between the low-cholesterol and combined higher 
cholesterol groups (52.9 versus 52.3 points, P=0.63).  
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Figure 6. Baseline cholesterol and physical (PCS) and mental (MCS) quality of life  in old 
age in 2000. 
The Physical component summary (PCS) and Mental component summary (MCS) scores in 2000 
according to the baseline serum cholesterol levels (5.0 mmol/L  vs. <5.0 mmol/L) measured in 
1964-1973. PCS and MCS were calculated using the RAND-36 scales. Adjusted for age, systolic 
















Figure 7. Baseline cholesterol and health-related quality of life (RAND-36) in old age in 2000. 
Baseline cholesterol and health-related quality of life (RAND-36) in old age in 2000. In all RAND-36 
scales a score of 100 is the best possible. Abbreviations ( and P-values) for the RAND-36 scales: 
PF = Physical functioning (P=<0.001), RP = Role limitations due to physical health (P=0.34) , 
BP= Bodily pain (P=0.03), GH= General health (P=0.08), VT= Energy/vitality (P=0.49), SF= So-
cial functioning (P=0.13), RE= Role limitations due to mental problems (P=0.36), MH= Mental 
health/emotional well-being (P=0.86). In all scales the scores were adjusted for age, baseline 
systolic blood pressure and BMI.
10.2 ALCOHOL
10.3.1 BASELINE
Among the 1.808 participants in this substudy, reported mean alcohol consumption 
in 1974 was 159 g/week (SD 153, median 123 g/week, interquartile range 56 to 
238). Several cardiovascular risk factors measured in 1974 became progressively 
more prevalent with increasing alcohol consumption (0, 1 to 349, and 350 grams/
week). Also reported weight gain from the age 25 years was positively associated 
















 tness in the three groups in 1974 showed that higher alcohol consumption was 
associated with worse pro les. 
10.3.2 THE DEVELOPMENT OF ALCOHOL CONSUMPTION DURING FOLLOW-UP
Age-adjusted alcohol consumption during the 29-year follow-up in those survivors 
who reported their current consumption in 2000 (n=960) was relatively stable in 
lower categories, but decreased markedly in the highest category.
In the 2000 survey (n=1.215), reported mean consumption was 117 g/week (SD 
137, median 70 g/week, interquartile range 28 to 154). Alcohol consumptions in 
1974 and 2000 were signi cantly correlated (r=0.53, P<0.0001). 
In 1986, serum gamma GT activity measured in 235 men was signi cantly 
correlated with the reported alcohol consumption (r= 0.41, P<0.0001).
10.3.3 MORTALITY DURING FOLLOW-UP
During the 29-year follow-up, 499 men (27.6% of the initial 1974 cohort) died. 
Crude mortalities in the three groups were signi cantly different, survival curves 
are shown in Figure 6. Mortality was signi cantly higher in the highest baseline 
category of reported alcohol consumption (37.6%), but fairly comparable in other 
groups (25.0% and 26.7% in abstainers and moderate drinkers, respectively). 















Unadjusted. P=0.01 (log-rank test).

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The proportion of cardiovascular deaths (determined up to 1999) of all deaths 
was 37.7% in the cohort, no signi cant differences were observed between the three 
alcohol consumption groups (P=0.5). Because alcohol consumption 350 grams/
week was associated with higher levels of risk factors at baseline, multivariate 
analyses using proportional hazards regression were also performed. In these 
analyses, zero and high alcohol consumption were compared with moderate intake 
(Table 11). When important risk factors (age, smoking, serum cholesterol and 1-hour 
post-load glucose) were added to the model, alcohol consumption was no longer a 
signi cant predictor of mortality.  
Table 11. Proportional hazards analysis of 29-year mortality in study groups.
Alcohol consumption 
group (grams/week)  in 
1974
Model A Model B* Model C*
0,  n=116 0.93 (0.64-1.35) 0.95 (0.65-1.38) 0.99 (0.68-1.45)
1-349, n=1.519 (reference 
group)
1.0 1.0 1.0
>349, n=173 1.50 (1.14-1.94) 1.34 (1.03-1.74) 1.26 (0.96-1.65)
Model A: No adjustments
Model B: Adjusted for age and smoking
Model C: Adjusted for age, smoking, serum cholesterol and one-hour post-load glucose
 *Covariates simultaneously in the model
10.3.4 HEALTH-RELATED QUALITY OF LIFE IN 2000
In 2000, 87% (n=1.216) of the survivors responded to the questionnaire survey. 
Non-respondents (n=200) had a higher mean baseline alcohol consumption 
than respondents (181 g/week vs. 148 g/week, P=0.01). This was due to a greater 
proportion of high alcohol consumption among non-respondents (12.7% vs. 8.1%), 
while proportions of abstainers were the same (6.6%). In 2000, over 90% were 
retired but 97-99% were home dwelling without signi cant differences between 
the three groups. Risk factor differences between the groups had diminished 
among respondents, but there were still signi cantly more smokers (P=0.001) and 
signi cantly less regular exercise (P=0.03) among the high alcohol consumption 




Health-related quality of life was assessed with the RAND-36 questionnaire in 
2000. There were no signi cant differences in the component summary scores PCS 
or MCS between the alcohol consumption groups (Figure 8, adjusted for age).  The 
results were essentially similar when the data were further adjusted for smoking, 
systolic blood pressure, serum cholesterol and BMI. However, signi cant differences 
were seen when the quality of life was further accounted for deaths during follow-
up. When adjusted for age, both physical and mental health were clearly poorer 
in men with the highest alcohol consumption, but fairly similar between zero and 
moderate consumption (Figure 8). 
Figure 8.  Baseline alcohol consumption in 1974and health-related quality of life in 2000 as 
measured by RAND-36 component summary scores PCS and MCS for physical and mental 
quality of life, respectively.
The original PCS and MCS scores were calculated using the RAND-36 scales. Based on the original 
score, the new values of physical health and mental health (“Accounted for death”) estimate the 
proportion (in percentage) of participants who are likely to be healthy 1 year later. The transfor-
med values include deaths during the follow-up as described in the Methods section. P-values 






































Of the 1.658 men, 614 (37.0%) were never-smokers at baseline in 1974. 650 men 
(39.2%) had quitted smoking earlier. The number of cigarette smokers in the 
different groups according to the number of cigarettes smoked were 87 (5.3% of 
the total cohort), 119 (7.2%) and 188 (11.3%) in the groups of 1-10 cigarettes, 11-20 
cigarettes and more than 20 cigarettes daily, respectively. 
At baseline there were signi cant differences in age, BMI, weight gain from age 
25 to baseline, BP, cholesterol, triglycerides, one-hour post-load glucose, reported 
alcohol consumption and self-perceived health between the groups.
10.4.2 CHANGES IN SMOKING BEHAVIOR OVER THE STUDY PERIOD
In 2000 the current smoking status was gathered from 1.131 men. The median age 
of responders was 73 years (interquartile range 70 to 76 years). Mean response 
rate was 87.9 %.  
The cessation rate among smokers was large during the follow-up: from 69% 
of those smoking over 20 cigarettes to 82% in the group smoking 1-10 cigarettes 
daily at baseline. Thus, in the 2000 query, only 6.9% (n= 78) of the respondents 
were currently smoking.  
10.4.3 MORTALITY DURING FOLLOW-UP ACCORDING TO SMOKING 
 STATUS IN 1974  
During the 26-year follow up 372 men (22.4%) died. Figure 9. shows the association 
between the smoking status in 1974 and mortality by the year 2000. The amount of 
daily cigarettes predicted mortality in a graded manner (P<0.0001). Although two 
out of three (69%) had stopped smoking since baseline, only 56% of those smoking 
over 20 cigarettes a day at the mean age of 48 were alive at the mean age of  73, 
as compared to 84% of never-smokers.
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Figure 9. The association of smoking status and the number of cigarettes smoked daily at 
baseline in 1974 and mortality during the 26- year follow-up.
Arrows indicate the difference of survival in years between never-smokers and smokers of more 
than 20 cigarettes daily. Dotted line indicates survival to the mean age of 73 years.
Using the never-smokers as the referent group, Table 12 shows the risk of total 
mortality after adjustment for age only and further for age, baseline cardiovascular 
risk factors (BMI, cholesterol, SBP and 1-hour post-load glucose) and alcohol 
consumption. In the latter analysis the men smoking over 20 cigarettes daily at 
baseline had a total mortality risk that was over 2.5 fold of that of never-smokers.
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Table 12. Relative risk for total mortality during the 26 years of follow-up according to smoking 
status at baseline in 1974. Never-smokers as referent.
Smoking status in 1974 Model 1 * Model 2 †
 RR 95% CI RR 95% CI
Ex-smokers 1.21 0.93, 1.57 1.05 0.80, 1.37
1-10 cigarettes/day 0.95 0.54, 1.66 0.82 0.46, 1.47
11-20 cigarettes/day 2.01 1.38, 2.93 1.60 1.08, 2.37
> 20 cigarettes/day 3.14 2.35, 4.20 2.61 1.92, 3.54
* Adjusted for age.
† Adjusted for age, alcohol consumption, BMI, cholesterol, SBP and 1-hour post-load glucose 
at baseline. 
RR: relative risk; 95% CI: 95% confi dence interval, BMI: Body Mass Index, SBP: systolic blood 
pressure
10.4.4 HEALTH-RELATED QUALITY OF LIFE IN 2000
The association between smoking status in 1974 and age-adjusted HRQoL in 2000 
is illustrated as RAND-36 scales in Figure 10.  
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Figure  10. The association of smoking status at baseline in 1974 and HRQoL as RAND-36 
scores in 2000.
Abbreviations for the RAND-36 scales: PF = Physical functioning, RP = Role limitations due to 
physical health, BP= Bodily pain, GH= General health, VT= Energy/vitality, SF= Social functioning, 
RE= Role limitations due to mental problems, MH= Mental health/emotional well-being. Adjusted 
for age. P-values above bars depict the overall difference between groups. 
(*) denote statistical signifi cance seen in PF, GH, and VT between never-smokers and men smo-
king >20 cigarettes, using Bonferroni’s correction for multiple comparisons.
The never-smokers had the highest (best) scores in all eight of the RAND-36 
scales, although the differences were not statistically signi cant for the scales 
expressing the mental and social aspects of the quality of life (Social functioning, 
Role limitations due to mental problems, Mental health). Compared to smokers, 
especially large differences were seen in the scales of Physical functioning and Role 
limitations due to physical health, where never-smokers gained 13.7 and 11.7 higher 
points, denoting a decline of 17 and 16 per cent, respectively, for those smoking over 
20 cigarettes a day (Figure 10). Compared to heavy smokers, the never-smokers in 
the cohort lived 10 years longer (Figure 9). Meanwhile, the difference in their level 
of disability, as suggested by the 13.7 point difference in the Physical functioning 
score, was equal to an age-difference of 10 years when compared to the age- and 
sex-matched general Finnish population norms. 40   
As in mortality, those who had quitted smoking before baseline examinations 
in 1974 did not generally seem to reach the RAND-36 points of never-smokers 































10.5 CARDIOVASCULAR RISK PROFILE 
10.5.1 BASELINE CHARACTERISTICS IN 1974
For the substudy V, the mortality and old age quality of life of 593 men with low 
cardiovascular risk pro les in midlife were compared to 610 men with high risk 
pro les in midlife during a follow-up period of 26 years. All risk factor levels 
measured in 1974, and reported BMI at age 25 for the two groups were signi cantly 
lower at baseline in the low-risk group. Self-rated physical condition in 1974 was 
clearly better in the low-risk group (P<0.0001), whereas differences in self-rated 
general health were smaller, although statistically signi cant (P=0.03). In 1974, the 
proportion of men reporting their general health as “poor” or “very poor” was 3.1% 
and 4.1% in the low-risk and high-risk groups, respectively (P=0.36).
10.5.2 MORTALITY OVER THE STUDY PERIOD
Mortality data was gathered up to December 31, 2002. By this time altogether 303 
(25%) men had died, 127 (21%) in the low-risk group and 176 (29%) in the high-risk 
group. (Figure 11.) The 29-year follow-up mortality was thus 54% higher (HR 1.54, 
95% CI 1.19-2.00) in the high-risk group. When adjusted for age, weight at age 25 
years and subjective health in 1974, the high-risk pro le in middle age prevailed as 




Figure 11. Survival curves of the baseline low and high cardiovascular risk  
Unadjusted. P=0.001 (log-rank test).
10.5.3 HEALTH-RELATED QUALITY OF LIFE IN 2000 
For the 2000 survey, the average age among survivors was 73 years (SD 4). The 
response rate was 90.7% for the low-risk and 88.5% for the high-risk group. 
 The men belonging to the high-risk group in 1974 reported a higher BMI, 
higher prevalence of smoking, and higher fasting blood glucose values in 2000 
than the men in the low cardiovascular risk group. In contrast, differences in blood 
pressure and serum cholesterol had diminished, although men in the high risk group 
still reported more hypertension in 2000. They also reported a signi cantly more 
sedentary lifestyle and a higher prevalence of diabetes, congestive heart disease, 
pulmonary disease, and musculoskeletal disease. 
The HRQoL of surviving participants was assessed with the RAND-36 instrument. 
In the low-risk group, all eight scales of RAND-36 indicated consistently better 
quality of life. Differences were statistically signi cant (P<0.05) for Physical function, 
Role physical, Bodily pain, General health and Social functioning (Figure 12.). The 




functioning and Role limitations due to physical problems, respectively, indicating 
a decline of 10 % and 15 % , respectively, for the group with high cardiovascular 
risk factor status at baseline. Of the two component summary scores only PCS, but 
not MCS was signi cantly different between the groups. 
Figure 12. The age-adjusted association of risk status at baseline in 1974 and HRQoL as 
RAND-36 scores in 2000. 
Abbreviations for the RAND-36 scales: PF = Physical functioning, RP = Role limitations due to 
physical health, BP= Bodily pain, GH= General health, VT= Energy/vitality, SF= Social functio-
ning, RE= Role limitations due to mental problems, MH= Mental health/emotional well-being. 



































10.6.1 BASELINE CHARACTERISTICS IN 1974
The cohorts with low and high midlife risk status which were identi ed for substudy 
V were also used for this substudy examining the effect of midlife cardiovascular 
risk factors on the negative and positive affect in old age. 593 healthy men with low 
cardiovascular risk pro les in midlife were compared to 610 healthy men with high 
risk pro les in midlife. Thus the baseline data in 1974, as well as the RAND-36 scores 
are the same as displayed for substudy V. Mortality follow-up was through 2002.
10.6.2 PSYCHOLOGICAL WELL-BEING IN 2002-3
To evaluate psychological well-being, a questionnaire was sent to survivors (454 
men in the low risk and 418 in the high risk group) in 2002-2003.  336 men in the 
low-risk group and 297 men in the high-risk group responded to this survey, giving 
response rates 74% and 71%, respectively.  Non-respondents and respondents in 
2002-3 had similar PCS scores in 2000, but scores for MCS tended to be lower 
among non-respondents. Of the respondents, 99% and 98% were home-dwelling, 
94% and 97% were retired, and 85% and 90% were currently married in the low and 
high-risk groups, respectively. All these differences between groups were statistically 
non-signi cant.  The data further emphasize the similar socioeconomic status of the 
two groups. Despite higher mortality in the high-risk group and selective survival, 
the gradient in risk factors between the groups had prevailed although they were 
somewhat reduced as compared to baseline. 
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Factors related to psychological well-being and attitudes towards life are shown 
in Table 6. The mental well-being of the low and high cardiovascular risk groups 
in 2002-3 is presented in Table 13.







Satisfi ed with life, yes/no (%) 318/11 (96.7) 272/20 
(93.2)
0.02
Feeling needed, yes/no (%) 118/210 (36.0) 92/198 (31.7) 0.13
Having plans for the future, yes/
no (%)
222/98 (69.4) 185/105 
(63.8)
0.07
Having zest for life, yes/no (%) 327/4 (98.8) 284/9 (96.9) 0.05
Feeling of depression, never or 
seldom/at times or often (%)
192/136 (58.5) 157/134 
(54.0)
0.13
Feeling of loneliness, never or 
seldom/at times or often (%)
288/40 (87.8) 257/37 (87.4) 0.56
Positive life orientation, yes/no (%) 71/265 (21.1) 47/250 (15.8) 0.04
How do rate your life course on a 
scale from 4 =worst  to 10 = best, 
mean (SE)
8.6 (0.04) 8.5 (0.04) 0.05
How do you rate your present 
happiness (0=very unhappy, 
10=very happy), VAS mean (SE)
7.7 (0.09) 7.3 (0.09) 0.001
Zung score, points (SE) 34.3 (0.4) 36.0 (0.4) 0.007
Continuous variables (mean with SE) are adjusted for age.
* Percentages are calculated from the actual number of respondents. 
VAS= visual analogue scale (10 cm) 
Although not all differences are statistically signi cant, the data are consistently 
better in the original low-risk group as compared to the high-risk group. Signi cant 
differences were seen in life satisfaction, feeling of happiness assessed with VAS, 
positive life orientation as a whole and the Zung depression score.
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The difference in the feeling of happiness (VAS) was tested further with 
multivariate analysis. The difference between the low and high-risk group prevailed 
(P=0.01) after adjustment for age, years of education, self-rated health in 1974, 




With the increase in longevity also the prevalence of chronic diseases and subsequent 
disability and functional impairment among the population is expected to rise. Good 
quality of life during these additional years is thus essential both from the individual’s 
and society’s point of view. Person reported information on how individuals consider 
the impact of disability or illness on their functioning or well-being has become 
a vital addition to the global assessment of health. This has only recently become 
possible in a large scale following the introduction of questionnaires that are valid 
and reliable as well as easy to use.
The studies presented in this thesis investigated the impact of lifestyle and 
modi able risk factors, which all affect cardiovascular health in the long term, 
on mortality and HRQoL. The hypothesis was that since much of the illness and 
disability in older people is related to cardiovascular risk factors in midlife, lower 
risk factor status not only postpones death, but also reduces disability and in rmity, 
which is then illustrated by better quality of life in old age.
Negative levels of all these risk factors examined: weight gain, alcohol, cholesterol 
and smoking individually, as well as in combination in midlife all led to diminished 
life expectancy, as could be anticipated in the light of previous studies. The novel 
 nding in these studies is that in addition to a shorter life span, these risk factors 
are associated with signi cant reductions especially in the physical components of 
HRQoL, and in most cases, also in the social and mental domains of quality of life.
11.2 DATA AND METHODS
The especially long follow-up time of the study cohort presents a distinctive approach 
to observe subsequent health consequences of different cardiovascular risk factors in 
midlife. The results are based on a large cohort of men who were all healthy without 
any chronic diseases or medication at baseline. The cohort is quite homogenous: 
All the men were from higher socioeconomic strata with similar job status mostly 
belonging to the professional executive grade. This is an asset in evaluating quality of 
life because social class has an apparent impact on morbidity and mortality. 306 The 
availability of data on several risk factors at baseline has made i t possible to perform 
extensive multivariate adjustments for potential confounding factors.  Mortality 
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follow-up with national registers was reliable and 100% complete, and during the 
follow-up of up to 39 years there were a substantial number of mortality endpoints. 
HRQoL was measured with a widely used and validated instrument (RAND-36) 
with a good overall response-rate, ranging from 71% to 91 % in the substudies.
11.3 WEIGHT GAIN
This substudy examined the effect of weight change from the age of 25 to the 
average age of 47 on mortality and health-related quality of life. In this cohort, 
excess mortality was associated only with the largest increase in weight,  15 kg 
(equivalent to BMI change >4.7 kg/m2), despite the long follow-up time up to the 
average age of 73 years. At the other end, zero or negative weight change was not 
associated with increased mortality. In contrast, impaired quality of life in old age 
was directly connected with earlier weight gain. The association was strong and 
graded in most of the quality of life scales, and independent of both weight at 25 
years of age and weight in old age. Those men who had avoided weight gain during 
midlife had clearly the best quality of life in old age. Even the lowest weight gain 
(4 kg) until midlife impaired HRQoL in old age, 26 years later, compared to zero 
weight change, with clinically meaningful (over 3 points)  impairments in all of the 
RAND-36 scales except Physical functioning. These results are in accordance with 
the study of employed Finnish men and women in which BMI weakly predicted 
death, but was linearly correlated with subsequent work disability, 307 as well as 
with the parallel results from the ELSA study data 308.
The study population was born and lived their adolescence in a society th at was 
less prosperous than today. Even in 1974 when the average age of the participants 
was 47 years, only 7% were obese. Recent statistics from Finland and elsewhere 
in the western world show that 20% to 30% of middle-aged population are obese, 
and an increasing proportion of population in af uent societies start gaining weight 
already in childhood and early adolescence. 128 In 2004 in the United States, 17% 
of children and adolescents were overweight.309 
Disability-associated health and social care costs are expected to rise with the 
growing numbers of overweight and obese older people. 309 This is illustrated by 
a study using U.S. population data showing that overweight persons used more 
health care services and missed more days from work.310 In a Swedish follow-up 
study of 60.000 participants, overweight and obesity in young adulthood were 
associated with a signi cant risk of premature disability pension later in life.311 
Cross-sectional data from a U.S. household sample indicated that the individual 
impact on physical HRQoL was similar for obesity, poverty, smoking and heavy 
drinking.312 Early disability and subsequent impairment of quality of life in a large 
segment of the population causes an enormous burden to the individuals, the health 
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care system and society at large, jeopardizing the bene ts of the favorable trend 
seen in other cardiovascular risk factors.
Controversies exist over whether overweight and obesity are independent 
cardiovascular risk factors, or whether they play through associated risk factors. In 
this substudy, weight gain was associated with baseline cardiovascular risk factors, 
(blood pressure, cholesterol, triglycerides and post-load glucose), which are in the 
causal pathway of the development of diabetes and cardiovascular diseases. There 
was no available information of risk factor levels at age of 25, but few men were 
overweight at that age, and less than 1% (n=11) were obese. According to earlier 
studies it is unlikely that elevation of other risk factors such as blood pressure, lipids 
or glucose would precede weight gain. 313 153 
It is also possible that the quality of life differences are not due to weight change 
as such, but to other, such as psychological or genetic factors associated with it. 
However, the dose-response characters of the association between weight gain and 
several of the RAND-36 scales disputes this possibility.
11.4 CHOLESTEROL
This substudy of nearly 40 years’ duration is one of the longest follow-up studies 
of cholesterol. The participating men were healthy and without hypolipidemic 
medications at baseline, and in midlife cholesterol level was not yet associated 
with subjective health.  The results provide evidence that serum cholesterol levels 
in young and middle-aged men have a long-term effect not only on cardiovascular 
health but also on total mortality and the quality of life in old age. 
Serum cholesterol predicted total mortality signi cantly and in a graded fashion. 
The men with naturally low cholesterol levels had better long-term survival and 
better quality of life in old age. Although original cholesterol differences had largely 
diminished among the old survivors, the men with cholesterol level 5.0 mmol/L 
at baseline had the best prognosis. The apparent explanation for better functioning 
and well-being is that there is less cardiovascular disease, especially coronary heart 
disease, among men with low cholesterol. The results are in accordance with current 
guidelines to postpone death, but also demonstrate further advantage associated 
with lower cholesterol in midlife. 
The bene ts of very low cholesterol have been disputed. The Honolulu Heart 
Program showed that low blood cholesterol levels predicted a greater total mortality 
risk in older people. 195 The explanation given for this J-shaped curve of cholesterol 
levels and mortality has been that fatal diseases such as cancer, for example, may 
lower cholesterol in the terminal stage, giving the J-shaped association if only the 
 nal years are examined. 196
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It is equally important that low cholesterol is not associated with adverse effects 
on mental functioning during long term. It has been debated whether low or lowered 
cholesterol could have a negative effect on mental or cognitive function. In a meta-
analysis, Shin et al. found an inverse, non-signi cant association between LDL 
levels and depression, especially in those without lipid-lowering medication.314 In 
the present substudy no such trend could be found for the mental component of 
quality of life; in all, the mental element was not affected. 
11.5 ALCOHOL
Total alcohol consumption in Finland has doubled during the last 30 years. 
Subsequently, the alcohol-related morbidity and mortality have been increasing 
in the Finnish population. 315 Yet, due to the cardio protective effects of ethanol, 
light or moderate alcohol use is often recommended to enhance health. Alcohol 
consumption is usually a life-long habit and thus the health effects should also be 
considered in the long-term: the possible postponement of coronary heart disease 
316 may not be worth the possible negative effects on health later on. Therefore 
it is relevant to consider also other outcomes in connection with alcohol intake. 
Total mortality and health-related quality of life in old age were chosen as outcome 
measures for this substudy on alcohol effects during a 29-year follow-up.
In this male population alcohol use in midlife was signi cantly and in a graded 
fashion associated with several cardiovascular risk factors. Despite this, only the 
highest category of consumption was related to increased mortality during the long 
follow-up. Even this association was not statistically signi cant if baseline risk factors 
were adjusted for. Among survivors in 2000, midlife alcohol consumption was not 
associated with either physical or mental quality of life. However, high consumption 
was harmful to HRQoL if deaths during follow-up were accounted for. 
An important  nding was that being an abstainer did not show any particular 
disadvantages on health. This suggests that moderate alcohol consumption as such 
may not offer special health bene ts as compared to zero consumption. Taking into 
account the substantial harms of excessive alcohol use, these  ndings question the 
need to promote alcohol use for health reasons. 
Although there are many previous studies on alcohol and mortality, this study 
has special strengths for studying the effects of alcohol itself. Important confounders, 
socioeconomic class and co-morbidity at baseline have been reduced, other 
cardiovascular risk factors are taken into account, the follow-up time of mortality 
is almost 30 years, and there is information of alcohol consumption at different time 
points of the follow-up with the original differences between the groups persisting. 
In general, respondents tend to underreport their alcohol intake in surveys.317  
However, a more detailed history taking such as asking the amount of speci c 
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beverages seems to result in higher reported consumption. 318 In the study cohort, 
the reporting of alcohol consumption is regarded reliable by the consistent pattern 
of consumption over the decades. The tracking of the consumption from 1974 to 
2000 was good, and the reported alcohol intake was signi cantly correlated with 
several risk factors known to be associated with alcohol consumption. In addition, 
reported alcohol consumption was also associated with serum gamma GT, a liver 
function test, which can also be applied to indicate alcohol consumption 319. 
An important question as to alcohol consumption is the long-term trade-off 
between harmful and possible bene cial effects. In this study, the long-term effects 
of alcohol on mortality and health were unexpectedly quite neutral. This suggests 
that harmful effects associated with greater alcohol consumption may in fact be due 
to factors other than alcohol, such as smoking, hypertension or weight gain, which 
cannot be distinguished in cross-sectional studies. And at the other end, these results 
indicate that alcohol is not needed for successful aging, and it is simultaneously 
possible to delay death and maintain a good quality of life without drinking moderate 
amounts of alcohol. Although alcohol consumption as such seemed to be less harmful 
when adjusted for smoking and other cardiovascular risk factors (and vice versa 
zero consumption was less bene cial), it can be debated whether it is applicable to 
adjust alcohol consumption too extensively. Alcohol use contributes to weight gain 
320, high blood pressure and lipid abnormalities, and these factors are evidently in 
the pathogenetic trail between alcohol and adverse outcomes such as mortality. 
Also counting only survivors in old age can produce a bias because those who 
have been able to cut their drinking may be better off. Therefore, in this study also 
deaths were accounted for and in these analyses greater alcohol consumption had 
a noticeably harmful effect on HRQoL. 
11.6 SMOKING 
 In this substudy, smoking status in middle age predicted mortality and health-related 
quality of life in old age in a cohort of men who were healthy and socioeconomically 
similar at baseline.  Mortality and HRQoL showed a dose-dependent relationship 
to the number of daily cigarettes smoked with heavy smokers suffering the greatest 
loss on these end-points. In spite of the 69% cessation rate during follow-up, 44 % 
of those who were smoking more than 20 cigarettes daily 26 years earlier had died 
compared to 16% in the non-smoker group, and those who survived to the mean age 
of 76, had a signi cantly lower HRQoL than never-smokers as measured with the 
RAND-36 instrument. Compared to never-smokers, they had worse scores in all 8 
RAND-36 scales, from 3.9 points less in Social functioning up to the overwhelming 
13.8 points less in Physical functioning.   
Heavy smokers had  a total mortality risk that was over 2.5 fold of that of never-
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smokers and over two-fold of those who had quit by 1974. This mortality rate is 
larger than in previous studies, but similar to that found in the British doctors’ study. 
239 The men smoking 11-20 cigarettes daily had a 90% higher mortality than never-
smokers. However, smoking 10 cigarettes or less daily in midlife did not increase 
mortality in the study cohort, but the number of men in this group was small and 
the  nding is not statistically signi cant. It is also possible that many men in this 
group were initially intermittent smokers explaining the lower mortality. Also the 
cessation rate during follow-up was greatest in this group: only 8% were smoking 
in 2000.
Those who had stopped smoking already by middle age did still have a higher 
mortality risk during follow-up than never smokers. It has been shown that mortality 
risk is reduced to the level of never smokers after 10 or more years of smoking 
cessation. 321 322 In this cohort, however, the mortality risk of quitters remained 29% 
higher even though they had quit more than 25 years before. This unexpectedly 
poor outcome in spite of early cessation may imply that the men in the quitters 
group have formerly been heavy smokers. One might assume that those who had 
quit smoking had done so due to an underlying disease, but in the study cohort the 
participants were all healthy with no evidence of chronic diseases in 1974.  However, 
ex-smokers did report poorer self-perceived health than never smokers already at 
baseline. But it is of note, that as seen in mortality, this trend persisted during the 
26 year follow-up: they still reported a poorer HRQoL in 2000 in all RAND-36 
scales and subsequently in the physical and mental component summary scores 
PCS and MCS.  However these differences were not large, and cannot be compared 
to the overwhelming effect that long-time heavy smoking has on these endpoints.
The fact that there is no update of the changes in the participants’ smoking habits 
between 1974 and 2000 could be regarded as a source of bias. The cessation rate 
during follow-up is large, but this re ects the real-life change in smoking habits of 
educated men from 1974 to 2000 in Finland 323 and elsewhere 246. However, in the 
present study only baseline smoking status is observed in relation to the endpoints 
in 2000, and the number of men who took up smoking in between is very small. In 
fact, the high rate of cessation during follow-up is liable to have diluted some of the 
harmful effects of smoking in this cohort, since compared to smoking, quitting itself 
has been shown to be bene cial for HRQoL. 253  Cessation of smoking after baseline 
may be due to illness which in turn negatively affects the HRQoL, possibly showing 
relatively better scores for smokers in 2000. Compared to a cross-sectional setting, 
the longitudinal design in the present study actually helps elude the possible bias.
In 1974, the smokers reported their perceived health status to be worse than non-
smokers already at baseline, assessed with the 5-step health measure.  A previous 
study on short-range smoking and SF-36 failed to show signi cant differences.324 
Yet a study in a cohort of healthy Brazilian students demonstrated that the HRQoL 
of smokers differed already in the  rst years of smoking as non-smokers showed 
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signi cantly better SF-36 scores than smokers in Physical functioning, Bodily 
pain, General health and Vitality. 325 These differences were attributed more to the 
smokers’ psychological pro  le than to tobacco itself. This would imply that those 
who are apt to take up smoking may have intrinsic psychological features, which 
are also mirrored in their quality of life before tobacco has had its effect on HRQoL. 
An early age of onset of smoking has been associated with a poorer health-related 
quality of life and reduced life satisfaction.326 327  Thus it is possible, that also in our 
cohort genetic factors, earlier life phenomena and psychological features may be 
re ected in the baseline differences of HRQoL between the groups.  
11.7 CARDIOVASCULAR RISK PROFILE
Major coronary risk factors, particularly smoking, elevated cholesterol and blood 
pressure strongly predict long-term cardiovascular morbidity and mortality. 86 Since 
many of these risk factors are preventable, an essential question is whether risk-
factor modi cation in the long-term increases morbidity and disability in old age 
by postponing death. 
The results of this substudy show that low levels of cardiovascular risk factors 
in middle age predict lower total mortality and also better quality of life with less 
disability in old age, 26 years later.  In line with earlier studies 245  328 the results of this 
substudy indicate that by keeping cardiovascular risk factors low, it is simultaneously 
possible to delay death, reduce cumulative morbidity and maintain better quality 
of life. At the same mean age of 73 years, men with an earlier history of low levels 
of risk factors had fewer chronic diseases, better functioning and better HRQoL 
than men with high risk status. Comparison of the present RAND-36 results with 
Finnish population data 40 showed that the pro le of the low-risk group was similar 
to that of 45-54-year old men in the general population. It has been estimated 
that each 1-point difference of the RAND-36 Physical component summary (PCS) 
score would mean a postponement of disability by one year. 45  Thus the three point 
difference seen in this study population between the low vs. high risk groups would 
mean a suspension of the onset of disability by three years in old age for those with 
favorable risk factor levels in midlife. In addition to the personal gain, delaying 
geriatric care by three years would reduce the  nancial burden on the health care 
system considerably. At the same time, the extended mortality data suggest that 
from 2000 to 2002 the total mortality is accelerating in the low risk group and that 
it is even larger than in the high risk group. These comparisons thus lend support 
to the Fries’ theory of the compression of morbidity. However, the follow-up time 
of the cohort must be extended with regular disability measurements beyond this 
point to settle this issue. It is possible that low- and high-risk groups would differ 
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genetically or because of intrauterine conditions, 329 making prevention less feasible. 
However, the fact that the reported BMI at age 25 did not differ much between groups 
suggests that more important differences in risk factors would not have developed 
until midlife. Subsequently, for maximum bene t, active intervention to reduce 
risk factors should begin in young adulthood or midlife at the latest. Intervention 
started in old age may reach only a limited part of the risk factor con guration or 
it may occur too late. In the present cohort, intervention after the age of 70 would 
have left a substantial part of the population uncovered, as one  fth had already 
died, 75% of them from potentially preventable cardiovascular diseases and cancer. 
Tuomilehto et al. demonstrated that even relatively modest lifestyle modi cations in 
midlife can effectively reduce the incidence of T2D 330 and have an impact on long 
term mortality 331. Bene ts of modern antihypertensive and cholesterol-lowering 
treatments in middle-aged individuals have been repeatedly demonstrated.  332  333 
The present results might actually re ect the success of early lifestyle modi cation 
as both high- and low-risk men had attended check-ups during the 1960’s and thus 
received health education before 1974. Based on their reported weight at  the age 
of 25, the increase in BMI during early midlife was signi cantly less in the low-risk 
group (1.95 kg/m2, SD 2.13 vs. 3.64 kg/m2, SD 2.63, P<0.0001). Probably for this 
reason the low-risk group had lower BMI and better glucose status and other risk 
factors at baseline in 1974 and they also reported better physical condition. In 2000, 
survivors in the low-risk group were still leaner and exercised more than did the 
high-risk group, but the earlier clear differences in blood pressure, cholesterol, and 
smoking had diminished or disappeared. This is probably due not only to selective 
mortality, but also to medical treatment for hypertension and hyperlipidaemia, as 
high risk men nevertheless reported a 1.8-fold higher prevalence of hypertension 
in 2000.   
The advantages observed in this study do not illustrate the full bene cial potential 
of low cardiovascular risk. There are several features which may have diluted the 
effect. First, the concept of “low” and “high” risk is somewhat relative, because even 
in the low-risk group the levels of risk factors at baseline were far from optimal and, 
for example, light smoking did not exclude low-risk status (see Data and methods, 
Table 9). According to modern standards, the group de ned as low-risk in 1974, 
might today actually be considered as an “intermediate-risk” group. Also, in order to 
be categorized as high-risk, the participant’s risk factors (except post load glucose) 
had to be over the predetermined limits on two occasions, as described in Methods. 
Thus all men in the high-risk group had risk factors repeatedly, whereas men with 
more labile risk factor levels were included in the low risk group. Second, the long-
term follow-up of the cohort leads to selection through mortality as those with 
higher levels of risk factors were more probable to die. Third, the differences in 
cardiovascular risk status were seen to attenuate between the groups with time 
because of medications and possible changes in lifestyle, such as smoking. And 
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 nally, all men were from the highest socioeconomic class, which itself is a protective 
factor, and almost all men were also living at home with their spouses. All these 
factors have the tendency move the hypothesis toward null. 
11.8 PSYCHOLOGICAL WELL-BEING
Psychological well-being is an important part of health-related quality of life and an 
essential determinant of health and social outcomes. Being a generic instrument, 
the ability of the RAND-36 questionnaire to examine psychological well-being is 
limited. Thus the purpose of this substudy was to further address the relationship 
between cardiovascular risk factors in midlife and mental quality of life in old age. A 
questionnaire examining both negative and positive affect was sent to the surviving 
men in 2002-2003, with questions related to depression, optimism, positive life 
orientation and happiness. The association of cardiovascular risk factors and mental 
quality of life was analyzed by comparing the men with high cardiovascular risk 
status with the low risk group as described in substudy V. In addition to the results 
presented in substudy V showing lower mortality and better physical HRQoL for 
the low risk group, the present study demonstrates that low cardiovascular risk in 
midlife is also associated with better psychological well-being in old age.
In substudy V, despite a trend, the differences in RAND-36 scales indicating the 
mental aspects of HRQoL between groups did not reach the 3 point limit regarded 
as clinically meaningful. Furthermore, the 1.8 point difference for Mental health 
and the 2.6 point difference for Role limitations due to mental problems were not 
statistically signi cant. The 3.1 point difference in Vitality or the 3.4 point difference 
in Social functioning did not reach statistical signi cance, either. Thus, compared to 
RAND-36, in spite of the conceptual overlap, the methods used in substudy VI were 
better able to distinguish differences in psychological well-being among the groups. 
Although not all variables of well-being were statistically signi cant, the results 
were consistent and signi cant differences were observed in dimensions related to 
depression and feeling of happiness. However, merely showing that positive well-
being is related to good quality of life may simply re ect the absence of depressed 
mood. In the current analyzes the difference in the feeling of happiness between 
the groups prevailed after adjustment for the feeling of depression, suggesting an 
independent association between earlier risk pro le and later psychological well-
being. 
These results based on a long follow-up advocate some potential pathways for 
the associations of cardiovascular risk factors and psychological well-being. The 
difference in well-being may be explained by less morbidity in old age in the low-
risk group as suggested by the results in substudy V. Also, alcohol consumption 
was higher in the high-risk group at baseline. However, according to the results 
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in substudy III, moderate alcohol consumption did not affect the quality of life in 
the study cohort, and the inclusion of alcohol use in the multivariate analysis did 
not explain the difference in happiness between the groups. Irrespective of the 
exact underlying mechanism, the present results suggest an important extra bene t 
of cardiovascular prevention in men – happier older years. Because positive life 
orientation has been shown to protect against institutional care and mortality in 
individuals over 75 years of age during a 10-year follow-up, 293 the full potential of 
low cardiovascular risk may yet to be seen in the present study population with an 
average age of 76 years. 
The differences between the low and high-risk groups are not large, but the 
results should rather be taken to support a mechanism - effect of cardiovascular 
risk and its sequelae also on psychological well-being. Besides, as discussed above, 
there are several factors, for instance features in the inclusion criteria for the low 
risk group as well as the SES of the cohort, which may have diluted the differences 
in outcome between the men with low and high risk status. Thus the effect could 
be expected to be more pronounced in the general public. 
The socioeconomic homogeneity of the cohort is of exceptional advantage in this 
study examining the association of cardiovascular risk factors and psychological 
factors because the confounding effects of social status on psychological well-being 
have been minimized. Happiness as well as cardiovascular risk factors are dependent 
also on socioeconomic factors. 334 For example, social isolation has been shown to 
cause psychological distress. Also low control at work has been associated with 
risk of cardiovascular disease.335  Psychological stress may increase the adoption 
of unhealthy choices such as smoking, alcohol consumption or sedentary lifestyle. 
Furthermore, psychosocial factors may have a direct effect on cardiovascular risk 
factors through neurohumoral activation.
11.9 LIMITATIONS
11.9.1 LIMITATIONS IN STUDY SETTINGS AND METHODS
With advancing age, non-participation or missing statements in questionnaires 
among the study subjects may increase. As measurements cannot be made after 
death and because those with poorer health are less likely to provide information, 
important data may be lost in end-of-life studies, favouring the group with the most 
deaths and missing data. 336  The 2000 questionnaire was acquired at a point when 
the mortality among the cohort was already considerable and signi cantly different 
between the groups. It is likely that men with less favorable risk factor status were 
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dropped from the analysis due to ill health, possibly weakening the negative effects 
of risk factors on HRQoL in these studies.
The 2002-2003 response rate in this elderly cohort was satisfactory (average 
73%) and there was no signi cant difference between the groups. The lower response 
rate as compared to the survey in 2000 (response rate 90%) may be due to the 
aging of the cohort, but another explanation is that the 2002-2003-questionnaire 
was substantially expanded as compared to the 2000-questionnaire. These  ndings 
have an important future implication for the Helsinki Businessmen Study population 
as the cohort ages, considering that the mean age in 2003 was 76 years.
11.9.2  LIMITATIONS IN RISK FACTOR MEASUREMENTS
11.9.2.1 Weight gain
A limitation pertaining substudy I is the fact that recalled weight at 25 years of 
age was used. However, recalled weight has been employed in several studies and 
it is considered reliable. 337  338 This is also supported by the fact that there was a 
relationship between weight at 25 years of age and subsequent weight. Also the 
validity of self-reported height and weight has been veri ed in earlier studies, 
although obese people, women more often than men, tend to underreport their 
weight.  However, the bias resulting from this has generally been small, 0.4 BMI 
units for men, according to an earlier study. 339 Because the waist circumference of 
the participants was not recorded, some medical problems that may be associated 
more with central rather than general obesity may have been omitted.  
11.9.2.2 Cholesterol
A limitation of substudy II was that only one baseline serum cholesterol measurement 
was available, and that the last cholesterol value in 2000 was based on self-report of 
the participants. However, the tracking of serum cholesterol in survivors was good 
and consistent over the years, as illustrated in Figure 2. in the original publication of 
substudy II. Additionally, serum cholesterol was measured in 131 men in 2003 and 
these levels appeared to be in accordance with the self-reported values in 2000. The 
proportion of men with low cholesterol (5.0 mmol/L) at baseline was relatively 
small, but this was a reality in Finland and many other western countries 40 years 
ago.
The cholesterol levels in old age were lower than in middle age. This trend has 
also been observed in the Finnish population since the 1970’s, and it has been 
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attributed to dietary changes in the population. 199 The men were healthy at baseline, 
and cholesterol-lowering medication was still rarely used at the time of the 1985 
survey, when only 3% of respondents reported taking these drugs. A total of 16% of 
men stated that they were taking cholesterol-lowering medication, mainly statins, 
in the 2000 survey, and this had an effect on the trend of lower cholesterol values 
in the 2000 questionnaire. Still, the bene ts of low cholesterol in this cohort mostly 
re ect the effect of naturally modi ed low cholesterol levels, and thus the results 
cannot be extrapolated to the effect achieved by the use of statins, for example.
11.9.2.3 Alcohol
In population studies abstainers often include former drinkers, who have stopped 
drinking due to illness or psychosocial problems. This may favor the outcome of 
moderate drinkers compared to abstainers. 340  Thus it is a limitation, that ex-drinkers 
were not identi ed in substudy III.  However, the relationship between alcohol and 
quality of life in old age was studied at a time point when the original differences 
in alcohol consumption still prevailed. Furthermore, the men with substantial 
problems related to alcohol use before midlife were excluded from the study, and 
moreover, all men were clinically healthy and working at baseline. While social 
class has an in uence on alcohol consumption and on alcohol-related mortality, 
341 the homogeneity of the study cohort diminishes the impact of this important 
confounding effect. 
While the homogeneity of the cohort offers evident advantages in investigating 
the effects of alcohol per se, it also poses some limitations. First, the cohort consisted 
mainly of low to moderate middle-aged drinkers and included only a limited number 
of heavy drinkers. This is attributable to the fact that the men were professionally 
active and healthy at baseline in 1974. For this reason, also those men who had 
evident alcohol-related problems before middle age were not included. On the other 
hand, this diminishes the possible bias that could result from failure to distinguish 
the former heavy users in the abstainers’ group. 
Secondly, because the cohort represents individuals who in midlife were healthy 
and professionally active irrespective of their alcohol consumption habits, the results 
cannot be extrapolated to younger men with similar consumption. Many alcohol-
related deaths occur in young age groups. 342  A 25-year follow-up study in young 
conscripts found a clear association between alcohol use (over 14 g/day) and risk 
of subsequent alcohol-related hospitalizations and deaths up to the age of 45.343 
Another limitation is that only the amount and not the pattern of drinking was 
investigated. The pattern of alcohol intake has been shown to have an impact on 
the health outcomes. 344 Risky drinking patterns hold special health hazards even if 
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total consumption does not surpass the limit of risk. 345 Another issue is the effect 
of the type of alcohol beverages (beer, wine or liquor) consumed, the signi cance 
and exact mechanisms of which are still controversial.346  
11.9.2.4  SMOKING
Limitations of substudy IV include that the age at which each smoker had started 
smoking was not recorded. But since the majority of smokers begin smoking 
during adolescence, 347 348  it can be speculated that in the present cohort many had 
already been smoking up to 30 years by the baseline in 1974, possibly explaining 
the differences in perceived health. Ideally the baseline examinations should have 
been made before this, but this of course was not feasible. 
Estimates for smoking status are based on self report and are not validated by 
biological tests in this study. However, self reported data on current smoking status 
have been determined to have high validity when compared with measured cotine 
levels, 349 also in the Finnish population350.
11.9.2.5 Risk factor profi le
An important limitation affecting the interpretation of the results of substudy VI 
is the absence of baseline data concerning psychological well-being and depressed 
mood. Differences between the groups may well have existed already at that time, 
as low-risk men rated their physical condition and general health better than 
high-risk men in 1974 as presented in substudy V.  These considerations do not 
necessarily nullify the conclusion that low cardiovascular risk is bene cial for well-
being – the perspective needs to be stretched out to an earlier point during the life 
course. It is also possible that genetic factors and early life phenomena primarily 
drive both happiness and cardiovascular risk – vs. intervening factors and events 
during lifetime. Obviously only life-long studies can resolve this issue. In the present 
cohort the low cardiovascular risk in midlife was primarily determined by genetic 
factors and life-style, because men had no preventive drug treatment at baseline. An 
important background factor is weight gain up to midlife, which was signi cantly 





All subjects were Caucasian men with high social status. This is a strength of the 
study because it partly removes the confounding effects of SES. Social status has 
a noticeable adverse in uence on morbidity and mortality 307 , as well as non-
participation in population surveys 351, and low socioeconomic status has been shown 
to decrease HRQoL. 352 But it is also a limitation as the study cohort is obviously 
selective: Thus, it is uncertain whether the results can be extrapolated to middle-
aged men of lower socioeconomic status, or to older persons or especially to women, 
and furthermore, whether these results can be applied to implement health policies 
for the general population.  
It may be regarded as a limitation that mortality and HRQoL are presented 
here separate of each other and therefore it is not possible to make an economic 
evaluation of these results. In promoting the reduction of risk factor levels on the 
patient level, it could also be motivating for them to be able to estimate the potential 
gain in disability free life years or the quality of these years associated with better 
risk factor status. Cost-utility analysis (CUA), for example the Quality Adjusted Life 
Years (QALYs) cannot be estimated directly by generic HRQoL measures such as 
RAND-36 alone, but a preference based measure is needed. However, correlations 
for SF-36 and CUAs have been demonstrated in different studies 353 354  and with 
these methods QALYs could be calculated from the RAND-36 points in these studies.
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12 SUMMARY AND CONCLUSIONS
Choices as regards diet, smoking and alcohol consumption seem to change life 
expectancy by many years. However, living longer does not necessarily mean better 
health or better quality of life, especially during the last years of life. Longevity may 
mean more years of disability and lower HRQoL during the achieved extra years: 
people who live longer also have more time to develop coronary heart disease or 
other chronic diseases causing disability and worse HRQoL. For instance, non-
smokers have shown to live longer with cardiovascular disease at the end of their 
life. 355 On the other hand, non-smokers have been shown to live with less disability. 
356 In the aging society, the functional status as well as mental well-being and social 
functioning during these achieved extra years is central for the aging individual as 
well as for the society. Can he live and enjoy life fully and independently or can he 
only manage by the help of others in an institution? Consequently, in addition to 
the more classical outcomes such as mortality and morbidity, HRQoL has become 
an increasingly essential end point in clinical practice and research especially in 
longitudinal studies measuring changes in health towards the old age.
The thesis of this study is that with favorable cardiovascular risk factor levels 
earlier in life, it is possible to both postpone death as well as the onset of disability 
and support well-being in old age. This hypothesis was examined in a cohort of men, 
who were healthy in middle age and were followed until the mean age of 73 years 
for mortality and quality of life. The results of this study indicate that lifestyle and 
different risk factor levels in midlife have a meaningful impact on the quality of these 
extra years. Leading a healthy lifestyle improves both survival and quality of life.
13 IMPLICATIONS AND FUTURE PERSPECTIVES
The impact of cardiovascular risk factors on health has been well documented. But 
while the risks are well known and means of effective prevention available, the 
implementation of preventive measures is still insuf cient. There is inadequacy in 
early identi cation of risk factors, there is delay in instigating corrective measures 
and  nally, there is failure in achieving the goals or treatment targets. For instance, 
in Finland, according to the National FINRISK 2007 Study, 36% of men aged 25-
104
Väitöskirjan ensimmäinen luku
34 years were smokers, 2/3 of men aged 35-64 had their cholesterol level over 5.0 
mmol/L and 2/3 were overweight or obese. 129 Approximately half of Finns with 
diabetes are unaware of their disease status. 357
The studies presented in this thesis substantiate that corrective measures should 
be started early. For instance, in substudy II the 39-year follow-up of the effect of 
cholesterol suggests that identifying and lowering elevated cholesterol levels should 
be done early in life. The substudy on smoking con rms that for maximum bene t, 
smoking should not be started at all. In this case the preventive effort should be aimed 
at teenagers. The same applies to other cardiovascular risk factors, and especially 
to early weight gain, considering the current obesity epidemic and the increased 
incidence of T2D at an early age and as signs of atherosclerosis are increasingly 
seen in individuals in their twenties.358
However, it is a common problem in primary prevention policies that persons 
with risk factors, but who are in a state of wellness, are not necessarily receptive 
to making changes in their lifestyle or motivated to start medication when they do 
not have any symptoms. Persons with riskier lifestyles may argue against health 
education and risk factor intervention by declaring that they prefer to enjoy life 
while they can, even if it is shorter.  Estimating the quality of the potential additional 
years gained by preventive measures could be highly motivating for the individual’s 
change of lifestyle. However, the argument of better quality of life in old age may 
be more meaningful for a person approaching the age of retirement and thus other 
measures must be utilized for those in young adulthood or middle-age. 
It has been argued, that the risk estimators in clinical use, such as ATP-III 334 
or SCORE 359, which estimate a 10 year risk of cardiovascular disease or death 
according to the individual’s risk factor pro le, may have too short a perspective, 
underestimating the life-time risk.360 361 This concerns especially women, whose risk 
of cardiovascular disease is lo wer in middle-age. 120  More studies with substantial 
numbers of participants with adequate baseline information, followed for the whole 
life-span are needed to identify and illustrate the impact of risk factors on health 
and survival at old ages. This would mean a long-term longitudinal study started 
before the risk factor has had time to produce its negative health effects, and with 
a follow-up time long enough to enable measuring the HRQoL during  “the last 
years” while taking also death into account.  However, the risk factor status of 
the participants may  uctuate due to changes in lifestyle or medication during a 
long follow-up. Ideally, in-between measurements of risk factors are thus needed. 
Studies of this kind are dif cult to conduct, but they are also required in order to 
evaluate the effect of modi able risk factors on health in regard to the hypothesis 
of the compression of morbidity. 362 363 
Although the patient’s well-being and quality of life have always been underlying 
priorities in patient care in clinical practice, only since the 1990’s have HRQoL 
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domains been accepted as important outcome measures in medical and social 
research. Self-perceived physical and mental health and function are now considered 
valid indicators of change in intervention studies, and HRQoL assessments are 
acknowledged as an integral part of patient information in clinical studies. 364 
The results from the studies in this thesis corroborate that by focusing on illness, 
important aspects of human health may be missed, and that morbidity and mortality 
statistics might not be a suf cient basis for setting preferences in one’s lifestyle or 
priorities in health care policy. 
The studies presented in this thesis bring new information to the usefulness of 
interventions for adding healthy years, rather than just additional years. These long-
term results suggest that successful control of cardiovascular risk factors in middle 
age is associated with fewer premature deaths, greater longevity, less costs for the 
health care and better quality of life in old age. This advocates the implementation 
and motivation of lifestyle modi cation and cardiovascular preventive measures in 




This thesis is based on the data of the Helsinki Businessmen Study, a follow-up 
study of originally over 3.000 men started in the 1960’s and continuing to the 
present day.  The studies were carried out at the Department of Medicine in the 
Helsinki University Hospital.
The “Founding Fathers” of the Helsinki Businessmen Study were Professor Tatu 
A. Miettinen, Professor Jussi Huttunen, Doctors Vesa Naukkarinen, Seppo Mattila 
and Torgeir Kumlin (deceased), as well as Professor Kalevi Pyörälä. In the beginning 
of the 1970’s they perceived the value of the data that had been collected earlier 
in health examinations conducted for middle-aged businessmen at the Finnish 
Institute of Occupational Health. Under the leadership of Professor Miettinen, 
several scienti c publications on various aspects of cardiovascular health in this 
cohort were subsequently published in high-pro le international journals during 
the 1970’s and 1980’s. Also four academic dissertations (Doctors Seppo Mattila, 
Vesa Naukkarinen, Hannu Vanhanen and Veikko Salomaa) were produced during 
the 1980’s. Although slumbering for some years in between, the aging study cohort 
was activated in 2000, when Professor Timo Strandberg with co-workers received 
a grant from the Sohlberg Foundation and the Helsinki University Hospital to 
investigate factors affecting successful aging in the Helsinki Businessmen Study. 
They were able to launch several projects assessing the rate and causes of functional 
and cognitive decline associated with aging. Ten years ago health-related quality 
of life (HRQoL) was yet an emerging outcome in clinical studies, and a far-sighted 
idea was to include measuring HRQoL in this aging cohort. I was invited in 2002 
to take part in the study to investigate the associations of the risk factors these men 
had in their middle age on HRQoL of their older days.
Today, the Helsinki Businessmen Study stands among the most prominent 
longitudinal studies of successful aging. The study is ongoing, with new questionnaires 
dispatched to the participants every three years. In spite of the average age of 80 and 
the ailing health of many of the participants, the response rate has remained high, 
70 % in 2007.  The next survey is planned for 2010, so with the continuing help of 
the participants, we hope to discover many new leads to the secrets of healthy aging.
On behalf of the study group of the Helsinki Businessmen study, this thesis gives 
me an opportunity to express our gratitude to the participants and our respect for 
the dedication they have shown by meticulously  lling out the many surveys we 
have sent them during the last ten years. 
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15.1 APPENDIX A: RAND 36-ITEM HEALTH SURVEY 1.0






2. Compared to one year ago, how would you rate your health in general now?
Much better now than one year ago 1
Somewhat better now than one year ago 2
About the same 3
Somewhat worse now than one year ago 4
Much worse now than one year ago 5
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The following items are about activities you might do during a typical day. Does your 











3. Vigorous activities, such as running, lifting 
heavy objects, participating in strenuous 
sports
[1] [2] [3] 
4. Moderate activities, such as moving a 
table, pushing a vacuum cleaner, bowling, or 
playing golf
[1] [2] [3] 
5. Lifting or carrying groceries [1] [2] [3] 
6. Climbing several fl ights of stairs [1] [2] [3] 
7. Climbing one fl ight of stairs [1] [2] [3]
8. Bending, kneeling, or stooping [1] [2] [3]
9. Walking more than a mile [1] [2] [3] 
10. Walking several blocks [1] [2] [3] 
11. Walking one block [1] [2] [3] 
12. Bathing or dressing yourself [1] [2] [3]
During the past 4 weeks, have you had any of the following problems with your work 
or other regular daily activities as a result of your physical health? (Circle One Number 
on Each Line)
Yes No 
13. Cut down the amount of time you spent on work or other 
activities
1 2 
14. Accomplished less than you would like 1 2 
15. Were limited in the kind of work or other activities 1 2 
16. Had diffi  culty performing the work or other activities (for 




During the past 4 weeks, have you had any of the following problems 
with your work or other regular daily activities as a result of any emotional problems 
(such as feeling depressed or anxious)?
(Circle One Number on Each Line)
Yes No
17. Cut down the amount of time you spent on work or other 
activities
1 2 
18. Accomplished less than you would like 1 2 
19. Didn’t do work or other activities as carefully as usual 1 2 
20. During the past 4 weeks, to what extent has your physical health or emotional 
problems interfered with your normal social activities with family, friends, neighbors, or 
groups? (Circle One Number)
Not at all  1
Slightly  2
Moderately 3
Quite a bit  4
Extremely  5
21. How much bodily pain have you had during the past 4 weeks? (Circle One 
Number)
None   1
Very mild  2
Mild   3
Moderate  4
Severe   5
Very severe  6
22. During the past 4 weeks, how much did pain interfere with your normal work 
(including both work outside the home and housework)? (Circle One Number)
Not at all  1
A little bit  2
Moderately  3
Quite a bit  4
Extremely  5
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These questions are about how you feel and how things have been with you during 
the past 4 weeks. For each question, please give the one answer that comes closest to 
the way you have been feeling.



















23. Did you feel 
full of pep?
1 2 3 4 5 6 
24. Have 
you been a 
very nervous 
person?
1 2 3 4 5 6 
25. Have you 
felt so down in 
the dumps that 
nothing could 
cheer you up?
1 2 3 4 5 6 
26. Have you 
felt calm and 
peaceful?
1 2 3 4 5 6 
27. Did you 
have a lot of 
energy?





1 2 3 4 5 6 
29. Did you feel 
worn out?
1 2 3 4 5 6 
30. Have you 
been a happy 
person?
1 2 3 4 5 6 
31. Did you feel 
tired? 
1 2 3 4 5 6 
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32. During the past 4 weeks, how much of the time has your physical health or 
emotional problems interfered with your social activities (like visiting with friends, 
relatives, etc.)? (Circle One Number)
All of the time   1
Most of the time  2
Some of the time  3
A little of the time 4
None of the time  5












33. I seem to get 
sick a little easier 
than other people 
1 2 3 4 5 
34. I am as healthy 
as anybody I know 
1 2 3 4 5 
35. I expect my 
health to get worse 
1 2 3 4 5 
36. My health is 
excellent 
1 2 3 4 5 
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15.2 APPENDIX B: RAND 36-ITEM HEALTH SURVEY 1.0 IN   
 FINNISH. RAND-36 ELÄMÄNLAADUN KYSELY,    
 SUOMENKIELINEN VERSIO (STAKES/KTL)







2. Jos vertaatte terveydentilaanne vuoden takaiseen, onko terveytenne yleisesti 
ottaen (ympyröikää yksi vaihtoehto)
Tällä hetkellä paljon parempi kuin vuosi sitten 1
Tällä hetkellä jonkin verran parempi kuin vuosi sitten 2
Suunnilleen samanlainen 3
Tällä hetkellä jonkin verran huonompi kuin vuosi sitten 4
Tällä hetkellä paljon huonompi kuin vuosi sitten 5
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Seuraavassa luetellaan erilaisia päivittäisiä toimintoja. Rajoittaako terveydentilanne
nykyisin suoriutumistanne seuraavista päivittäisistä toiminnoista? Jos










3. Huomattavia ponnistuksia vaativat 
toiminnat (esimerkiksi juokseminen, 
raskaiden tavaroiden nostelu, rasittava 
urheilu)
[1] [2] [3] 
4. Kohtuullisia ponnistuksia vaativat 
toiminnat kuten pöydän siirtäminen, 
imurointi, keilailu
[1] [2] [3] 
5. ruokakassien nostaminen tai kantaminen [1] [2] [3] 
6. nouseminen portaita useita kerroksia [1] [2] [3] 
7. nouseminen portaita yhden kerroksen [1] [2] [3]
8. vartalon taivuttaminen, polvistuminen, 
kumartuminen
[1] [2] [3]
9. noin kahden kilometrin matkan kävely [1] [2] [3] 
10. noin puolen kilometrin matkan kävely [1] [2] [3] 
11. noin 100 metrin matkan kävely [1] [2] [3] 
12. kylpeminen tai pukeutuminen [1] [2] [3]
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Onko Teillä viimeisen 4 viikon aikana ollut ruumiillisen terveydentilanne takia alla mai nittuja 
ongelmia tavanomaisissa päivittäisissä tehtävissänne? (ympyröikää yksi numero joka riviltä) 
Kyllä Ei
13. Vähensitte työhön tai muihin tehtäviin käyttämäänne aikaa 1 2 
14. Saitte aikaiseksi vähemmän kuin halusitte 1 2 
15. Terveydentilanne asetti teille rajoituksia joissakin työ- tai muissa 
tehtävissä
1 2 
16. Töistänne tai tehtävistänne suoriutuminen tuotti vaikeuksia 
(olette joutunut esim. ponnistelemaan tavallista enemmän)
1 2 
Onko Teillä viimeisen 4 viikon aikana ollut   tunne-elämään liittyvien  vaikeuksien (esim. 
masentuneisuus tai ahdistuneisuus) takia alla mainittuja ongelmia työssänne tai muis sa 
tavanomaisissa päivittäisissä tehtävissänne?  (ympyröikää yksi numero joka riviltä) 
Yes No
17. Vähensitte työhön tai muihin tehtäviin käyttämäänne aikaa 1 2 
18. Saitte aikaiseksi vähemmän kuin halusitte 1 2 
19. Ette suorittanut töitänne tai muita tehtäviänne yhtä 
huolellisesti kuin tavallisesti
1 2 
20. Missä määrin ruumiillinen terveydentilanne tai   tunne-elämän vaikeudet ovat 
viimei sen 4 viikon aikana häirinneet tavanomaista (sosiaalista) toimintaanne perheen, 
ystävien, naapureiden tai muiden ihmisten parissa?  (ympyröikää yksi vaihtoehto)
ei lainkaan  1
hieman   2
kohtalaisesti  3
melko paljon  4
erittäin paljon  5
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21. Kuinka voimakkaita ruumiillisia kipuja Teillä on ollut viimeisen 4 viikon aikana?
(ympyröikää yksi vaihtoehto)
ei lainkaan     1
hyvin lieviä     2
lieviä      3
kohtalaisia     4
voimakkaita     5
erittäin voimakkaita  6
22. Kuinka paljon kipu on häirinnyt tavanomaista toimintaanne (kotona tai kodin 
ulkopuo lella) viimeisen 4 viikon aikana? (ympyröikää yksi vaihtoehto)
ei lainkaan     1
hieman      2
kohtalaisesti     3
melko paljon     4
erittäin paljon     5
Seuraavat kysymykset koskevat sitä, miltä Teistä on tuntunut viimeisen 4 viikon 
aikana. Merkitkää kunkin kysymyksen kohdalla se numero, joka parhaiten kuvaa 
tuntemuksianne.  
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1 2 3 4 5 6 
30. ollut 
onnellinen




1 2 3 4 5 6 
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32. Kuinka suuren osan ajasta ruumiillinen terveydentilanne tai tunne-elämänvaikeudet 
ovat viimeisen 4 viikon aikana häirinneet tavanomaista sosiaalista toimin taanne 
(ystävien, suku laisten, muiden ihmisten tapaaminen)? (ympyröikää yksi vaihtoehto)
koko ajan   1
suurimman osan aikaa  2
jonkin aikaa   3
vähän aikaa   4
ei lainkaan   5






























1 2 3 4 5 
35. Uskon, että 
terveyteni tulee 
heikkenemään
1 2 3 4 5 
36. Terveyteni 
on erinomainen
1 2 3 4 5 
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3.490 men of high socioeconomic status, born 1919-1934 attend voluntary health 
checks at the Institute of Occupational Health in Helsinki. Data available n= 3.313 
men.
● Clinical  examinations including  weight, height, blood pressure
● Laboratory examinations including cholesterol, one-hour post-load glucose, 
 triglycerides from 1969
● Medical history
Questionnaire and invitation to examination to all surviving men, data available n=2.375 
● Clinical examinations including weight, blood pressure
● Laboratory examinations including cholesterol, triglycerides, glucose, ECG.
● Cardiovascular risk factors and lifestyle: including smoking, self-reported weight from age 
 25, alcohol consumption, physical activity 
● Self rated health and fi tness
● Cohort divided according to health and cardiovascular risk  status:
Dead n=68
No response/refused n= 867
Low risk group
n= 593
Healthy, no signs of 
CV disease. 




Healthy, no signs of 
CV disease. 
One or more CV risk 
factors.




mean age 48 years
2002-2003








Dead  n= 18
Postal questionnaire, demographics, laboratory tests at local 
heath care center.  n= 1.723, data available n= 1.399
Dead  n= 31 Dead  n= 43
2000
mean age 73 years
Low risk group 
of 1974
n= 489
High risk control 
group of 1974
n= 456
High risk control 
group of 1974
n= 456
Dead  n= 99 Dead  n= 152 Dead  n= 175
Dead  n= 244
Dead  n= 285
Mortality from registers. Cumulative death  n= 1.023
Postal questionnaire n= 2.286 . Data available n= 1.864.
● RAND-36
● self-reported weight
● cardiovascular risk factors
● diseases, medications




n= 900, data available n= 633
Low risk group 
of 1974
n= 336
High risk control 
group of 1974
n= 297
    1964-1973  
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